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IMPLANT COMPOSITIONS FOR THE malignant gliomas . Gliadel® has been on the market for 
UNIDIRECTIONAL DELIVERY OF almost twenty years and is the only FDA approved local 
THERAPEUTIC COMPOUNDS TO THE implant to treat glioblastoma multiforme . There are pres 
BRAIN ently no generic equivalents on the market . The polyanhy 
5 dride carrier in the Gliadel® implants is a co - polymer , 
This application claims the benefit of U . S . Provisional polifeposan , which consists of 1 , 3 - bis ( p - carboxyphenoxy ) 
Patent Application No . 62 / 197 , 739 , filed Jul . 28 , 2015 , U . S . propane and sebacic acid in a molar ratio of 80 to 20 . 
Provisional Patent Application No . 62 / 198 , 040 , filed Jul . 28 , Molecules of active ingredient are distributed through the 
2015 , and U . S . Provisional Patent Application No . 62 / 329 , polymer matrix , which controls drug delivery at the site of 
973 , filed Apr . 29 , 2016 , the entirety of which are incorpo - 10 the implant . The product is designed to deliver therapeutic 
rated herein by reference . levels of the drug that cannot be achieved with other routes 
of drug delivery , including i . v . and oral . It has been reported 
BACKGROUND OF THE INVENTION that the median survival of patients with Gliadel® wafers for 
recurrent glioblastoma was thirty - one weeks compared to 
1 . Field of the Invention 15 twenty - three weeks for those on placebo , although this was 
The present invention relates generally to the field of not statistically significant . Survival benefit was indeed 
pharmaceutics and medicine . More particularly , it concerns statistically significant in patients with newly diagnosed 
pharmaceutical implants for drug delivery and methods of glioblastoma , although the benefit is deemed as modest by 
use thereof . most ( ~ 2 months ) . 
2 . Description of Related Art 20 The increase in side effects such as seizures , wound 
There have been many therapeutic methods developed to healing difficulties , the development of cysts , and reactive 
treat brain cancer , including surgery , radiotherapy and che - brain edema seen with the Gliadel® wafers has been a major 
motherapy . The present invention relates to pharmaceutical concern to neurosurgeons wishing to use this product on 
compositions that have activity as anti - cancer agents and to their patients . Up to eight wafers can be implanted in a 
the methods for the treatment of cancer in patients . 25 patient following removal of the tumor . There have been 
Glioblastoma Multiforme is a grade 4 astrocytoma . It is an reports where some neurosurgeons have re - operated to 
aggressive cancer that grows from the supportive cells in the remove these wafers from patients due to severe adverse 
brain and is diffusely infiltrative . The current standard side effects . 
treatment is aggressive surgical debulking followed by com - Several theories have been proposed regarding the rea 
bined modality therapy of chemotherapy and radiation . 30 sons for increased side effects and toxicity of the Gliadel® 
Despite the neurosurgeon successfully resecting all visible wafers in patients when compared to a placebo . For implants 
abnormal tissue during surgery , there are normally many based on the biodegradable polyesters and polyanhydrides , 
cancer cells that extend well past the resection cavity and are there is a potential for toxicity from dose dumping ( burst 
still present in the patient after the surgery . The average effect ) , inconsistent drug release and the breakdown of the 
survival rate for patients with glioblastoma multiforme who 35 polymer from hydrolysis or enzymatic degradation . The 
have had aggressive treatments , including surgical resection , by - products of polyanhydride polymer degradation include 
radiotherapy and chemotherapy , has been reported to be the formation of carboxylic acids amongst other byproducts . 
about fourteen months . It has also been reported that less The presence of agents to prevent oxidation of the polymer 
than 30 % of patients survive two years . Long - term survival in the solid state may also contribute to these side effects . 
is extremely rare . 40 Irritation at the cellular level by these low molecular weight 
Billions of dollars have been spent over the past 30 years degradation compounds may be one of the causes of toxic 
on new therapies with survival benefits only increasing on side effects . Slight variations in the molecular weight of the 
the scale of months , not years , and presently no curative polymer may also result in higher levels of low molecular 
therapies exist . Outside of standard chemotherapeutics , anti weight fractions , which will biodegrade faster than the 
angiogenics have shown only minimal benefit . Currently , 45 higher molecular weight fractions in the polymeric carrier . 
researchers are working on individualized therapy based on Acidic by - products can also be generated during storage of 
specific genetic mutations of a patient ' s individual tumor . the polymers , which may influence the long term chemical 
Vaccines are being developed to combat some of these stability of the biologically active compound . Since these 
mutations . Local chemotherapy at the tumor resection site polyanhydrides are soluble in most organic solvents , the 
has also been attempted with some minimal degree of 50 incorporation of a therapeutic agent into such polymers 
success . From a scientific standpoint , trials have shown generally occurs using an organic solvent which dissolves 
statistically significant survival improvements , but a sur - the polymer and often times the anticancer compound , prior 
vival expectation of 15 months rather than 13 months may to the evaporation of the solvent to form the finished 
represent only a very modest improvement for the patient . delivery system . These organic solvents used to dissolve the 
Although researchers have successfully cured cancer in 55 polymers include dichloromethane , acetone , tetrahydro 
some animal models , this success has rarely been duplicated furan , and ethyl acetate and residual solvents in these 
in humans with glioblastoma . polymeric devices have their own inherent toxicity . Dichlo 
A variety of biodegradable polymers , including the poly - romethane is one of the most popular solvents reported in the 
esters and polyanhydrides have been reported in the litera - literature to prepare films or wafers , microparticles , and 
ture as carrier polymers for anti - cancer compounds . Of these 60 microcapsules of drug - containing biodegradable polymeric 
materials , polylactide - co - glycolic acid ( PLGA ) has been formulations . The FDA has classified dichloromethane as a 
extensively studied . However , although various biodegrad Class 2 solvent , which should be limited in pharmaceutical 
able polymeric materials have been tested for drug delivery , products due to its inherent toxicity . In 2012 , the limit for 
relatively few commercial products that have reached the this solvent in a pharmaceutical product was six hundred 
marketplace utilize either polyesters or polyanhydrides . 65 parts per million . The breakdown or erosion of a polyester 
One such product that has been marketed is the Gliadel® or a polyanhydride based delivery system at the site of 
wafer implant that contains carmustine for the treatment of implantation in the brain or at other sites of the body may 
US 9 , 956 , 172 B2 
cause the formation of particles or agglomerate of polymer or substantially prevent release of the drug into the cere 
that can irritate surrounding tissue , which may result in brospinal fluid in order to improve the therapeutic effect of 
adverse side effects . the drug ( e . g . , an chemotherapeutic and / or a steroid ) . 
Certain problems exist for current treatments for glioblas - In some aspects of the present invention , an anti - cancer 
toma multiforme . The current standard treatment for patients 5 compound is formulated into a multilayered ( e . g . , bilayered 
suffering from glioblastoma multiforme is to begin taking or trilayered ) wafer implant that can be delivered directly to 
oral temozolomide capsules two to four weeks after surgery . the wall of the cavity in the brain from where a tumor was 
Radiation treatments are usually initiated in a similar time removed , to increase survival rates in cancer patients . The frame . The delay allows for the wound to begin the healing slow release of the drug from the implant can allow for the process . The disadvantage of the delay is that cancer cells 10 absorption and distribution of the anti - cancer compound into continue to grow during this time period . the local environment of the brain to provide therapeutic Temozolamide can also display adverse side effects . levels of the active moiety over extended time periods , e . g . , Commercial capsules of temozolomide are available in to kill cancer cells in the brain . doses ranging from 5 mg to 250 mg . The drug has a short The composition of the drug - containing layer of the wafer biological half - life of approximately 11 / 2 hours and thus 15 
must be frequently administered to patients to maintain implant may include or comprise one or more drugs , a lipid 
therapeutic levels . Multiple side effects have been reported and a hydrophilic polymer and , optionally , one or more other 
for temozolomide including nausea , vomiting , constipation , additives . The implant may be applied to the inner surface of 
headache and fatigue . These side effects occur in greater the resection cavity in the brain following surgical removal 
than 30 % of patients taking temozolomide capsules . Other , 20 of the tumor . A second top layer can comprise one or more 
less common , side effects have also been reported . Various hydrophobic agents , which can reduce , prevent , slow , or 
compositions have been generated in an attempt to try to minimize the diffusion of drug from the implant into the 
alter the release of temozolamide , such as the tableted cerebrospinal fluid of the resection cavity . Through this 
microspheres described in U . S . Pat . No . 8 , 821 , 913 . property , this layer may promote unidirectional absorption 
Lipids have been studied for applications such as intra - 25 of drug through the inner wall in the cavity . The two layers 
muscular implants and excipients in parenterals and oral are preferably in a side - by - side configuration . An optional 
solid dosage forms ; however , major problems have been third layer may comprise a hydrophilic polymer , e . g . , to 
observed with implants and oral tablets that rely upon lipids further enhance bioadhesiveness of the implant to the wall of 
to retard drug release , include erratic and incomplete drug the resection cavity . When the third layer is used , the drug 
release performance . “ Tailing " , is a phenomenon , where the 30 containing layer of the implant may preferably be sand 
final 15 - 25 % of the drug remains locked in the wax matrix , wiched between the hydrophobic layer and the hydrophilic 
resulting in subtherapeutic levels of the drug substance . polymer layer . A hydrophobic coating may be applied to all 
Additional efforts to generate delivery systems have also surfaces of the wafer where drug release is not desirable . In 
resulted in various challenges . To resolve the erratic release some embodiments , this includes the sides of the wafer and 
properties and physical stability issues with lipid based 35 the hydrophobic layer , leaving the bioadhesive layer non 
systems , numerous researchers have included water soluble coated and therefore promoting drug release in a substan 
pore forming polymers such as polyethylene glycol in the tially unidirectional fashion . Thus , in some embodiments , 
formulation . Hydrophilic polymers have also been studied anti - cancer compounds that are ineffective when adminis 
as retardant carrier excipients in solid dosage forms , includ - tered via a given route of administration ( e . g . , by the oral or 
ing implants . However , the dissolution and swelling prop - 40 parenteral route ) and / or have difficulty in crossing the blood 
erties of these implants would result in high levels of drug brain barrier by the traditional routes of administration may 
being released directly into the brain cavity over a short nonetheless be administered to the brain . For example , 
period of time . For implants that deliver anti - cancer com - various anti - cancer agents that are toxic when administered 
pounds to the cavity of the brain following surgical removal ( e . g . , systemically or orally ) may be administered to a 
of the tumor , drug release over a period of 1 - 2 days would 45 subject in an implant of the present invention to achieve 
be ineffective since therapeutic levels of the drug need to be therapeutic concentrations in the brain . High temperature 
maintained over periods of weeks , not days . Furthermore , by curing of these implant compositions may be employed to 
releasing the drug directly into the fluid of the brain cavity , increase the adhesion of both the hydrophobic and hydro 
the concentration would be low resulting in minimal diffu - philic layers to the drug containing layer . 
sion of the active drug molecules across the surface of the 50 It has been found in various aspects of the present 
cavity into the brain . In addition , the drug would circulate to invention that biocompatible pharmaceutical wafer implant 
other normal portions of the central nervous system , possi - compositions comprising biologically active compounds to 
bly leading to side effects . Clearly , there is a need for treat tumors ( e . g . , malignant tumors ) can be prepared using 
improved methods and implants for the treatment of brain lipids as inert carrier materials and hydrophilic water soluble 
tumors . 55 pore forming polymeric agents to regulate the drug release 
rate . The wafers may optionally include one or more addi 
SUMMARY OF THE INVENTION tives ( e . g . , to improve processing and to control the rate of 
release of the active agent from the solid dosage form ; or a 
The present invention overcomes limitations in the prior preservative , antibiotic , or antimicrobial agent to reduce 
art by providing , in some aspects , multilayered implants or 60 microbial growth and / or infection ) . This combination of 
wafers that may be used , e . g . , to deliver a chemotherapeutic ingredients in the wafer or implant may provide for a 
agent and / or a steroid to the brain after the resection of a controlled release of the anti - cancer compound ( s ) at the 
brain tumor . For example and as noted herein , implants of tumor site , while causing little or no change in the pH at the 
the present invention can result in a slowed release of a drug site of implantation . Thus , in some embodiments , the wafer 
from the implant or wafer that may improve the therapeutic 65 or implant results in essentially no harmful release of 
effect of the drug ; additionally , in some aspects , a hydro - byproducts to irritate the cellular linings of the surrounding 
phobic coating on the implant may reduce , slow , minimize , tissues . 
US 9 , 956 , 172 B2 
In one aspect , the present invention relates to a biocom - some embodiments , the drug is a steroid . In some embodi 
patible drug delivery implant for positioning adjacent to a ments , layer a ) comprises both a chemotherapeutic agent and 
biological tissue for delivering one or more drugs thereto , a steroid . In some embodiments , layer a ) comprises a 
the implant comprising at least two layers , a drug - containing chemotherapeutic agent , and wherein the implant further 
layer having a drug elution surface to be positioned proximal 5 comprises the layer d ) , wherein layer d ) comprises a steroid . 
to the tissue , and , a further layer or layers comprising a Layer a ) may further comprise a steroid . The steroid may be 
lipophilic backing layer and / or a hydrophobic coating , said dexamethasone or dexamethasone sodium phosphate . In 
further layer or layers being positioned distal to the drug some embodiments , the chemotherapeutic agent is temozo 
elution surface , wherein : a ) the drug - containing layer com - lomide or paclitaxel ; and wherein the steroid is dexametha 
prises one or more drugs , a hydrophilic polymer or pore 10 sone . In some embodiments , the implant is substantially 
forming agent , and a biocompatible hydrophobic lipid or circular or elliptical in shape . In some embodiments , the 
polymer ; b ) the lipophilic backing layer comprises a bio implant is further defined as a wafer . The wafer or tablet may 
compatible hydrophobic lipid or polymer , and c ) the hydro - be configured for insertion into a resection cavity . The 
phobic coating comprises a biocompatible hydrophobic lipid implant or wafer may further comprise an additional thera 
or polymer and coats surfaces of the implant that are not to 15 peutic agent ( e . g . , an antibiotic , an antimicrobial agent , a 
be positioned proximal to the tissue and ; and further , when statin , an anti - fungal agent , an anti - viral agent , a steroid , an 
each of layers a ) , b ) and c ) are present , the lipophilic backing anesthetic , a local anesthetic , or a NSAID ) . In some embodi 
layer is positioned between the drug - containing layer and ments , the additional therapeutic agent is an antibiotic or an 
the hydrophobic coating . In some embodiments , the implant antimicrobial agent . In some embodiments , the implant does 
comprises layers a ) and b ) . In some embodiments , the 20 not contain an organic solvent . In some embodiments , the 
implant comprises layers a ) and c ) . In some embodiments , implant contains an organic solvent , or no more than a trace 
the implant comprises layers a ) , b ) and c ) . The implant may amount or a residual amount of the organic solvent . The 
further comprise a drug - permeable , hydrophilic layer d ) organic solvent may be ethanol , dichloromethane , acetone , 
positioned between the drug elution surface of the drug - tetrahydrofuran , or ethyl acetate . 
containing layer and to be positioned proximal to the tissue . 25 In some embodiments , the drug - containing layer com 
In some embodiments , the layer d ) does not contain the drug . prises 1 , 2 , 3 , or all of glyceryl behenate , stearic acid , 
The layer d ) may contain a steroid . In some embodiments , polyanhydroglucuronic acid , and / or polyethylene oxide . The 
the layer d ) contains the drug . In some embodiments , the lipophilic backing layer and / or the hydrophobic coating may 
layer d ) contains a steroid and the drug . In some embodi comprise 1 , 2 , or all of stearic acid , glyceryl behenate , and / or 
ments , the steroid is dexamethasone . In some embodiments , 30 chitosan . In some embodiments , the lipophilic backing layer 
the hydrophobic lipid or polymer in layers a ) , b ) , and / or c ) and the hydrophobic coating are made of the same or 
is a steroid or a fatty acid . The steroid may be a cholesterol . essentially the same compounds or mixture of compounds . 
In some embodiments , the fatty acid is a saturated fatty acid . In some embodiments , the lipophilic backing layer and the 
The saturated fatty acid may have 6 to 24 carbon atoms or hydrophobic coating together form a substantially homog 
12 to 24 carbon atoms . The fatty acid may be stearic acid , 35 enous hydrophobic layer . In some embodiments , the lipo 
palmitic acid , or a glyceride . In some embodiments , the philic backing layer and the hydrophobic coating comprise 
glyceride contains a mixture of monoglyceride , diglyceride , different compounds . The hydrophobic coating may consist 
and triglyceride . In some embodiments , the mixture contains of or consist essentially of glyceryl behenate . In some 
predominately diglyceride . The glyceride may be a glyceryl embodiments , the hydrophobic coating comprises glyceryl 
behenate or stearin ( tristearin ) . In some embodiments , the 40 behenate in combination with 1 , 2 , 3 , or all of stearic acid , 
hydrophobic lipid is glycerol behenate , a fatty acid , a palmitic acid , cholesterol , and / or chitosan . In some embodi 
cholesterol , a glyceride , a hydrogenated vegetable oil , ments , the drug - containing layer comprises glyceryl behen 
tristearin , or the like . In some embodiments , the hydrophilic a te and / or stearic acid , in combination with polyanhydrog 
polymer present in layer a ) and / or d ) is a polyether or a lucuronic acid and / or polyethylene oxide . The drug 
polysaccharide . In some embodiments , the hydrophilic poly - 45 containing layer may comprises glyceryl behenate , stearic 
mer is a polyethylene oxide , polypropylene oxide , or a acid , and polyethylene oxide . The drug - containing layer 
polyethylene glycol . In some embodiments , the hydrophilic may further comprises lipase , cholesterol , glyceryl tristear 
polymer is a polyethylene oxide or a polysaccharide . In ate , and / or poloxamer F - 68 . In some embodiments , layer c ) 
some embodiments , the polysaccharide is chitosan or poly - and / or layer b ) contain lipase . The drug - containing layer 
anhydroglucuronic acid . The hydrophilic polymer may com - 50 may comprise polyethylene oxide or polyanhydroglucoronic 
prise a mixture of a polyether and a polysaccharide . In some acid . The drug - containing layer may comprise polyethylene 
embodiments , the hydrophilic polymer is a mixture com - oxide , glycerol behenate , and / or cholesterol . The drug 
prising polyethylene oxide and chitosan . The hydrophilic containing layer may comprise 1 , 2 , 3 , 4 , 5 , 6 , 7 , or all of 
polymer may be polyethylene oxide or polyanhydroglu stearic acid , lipase , cholesterol , glycerol behenate , glyceryl 
curonic acid . In some embodiments , the hydrophilic poly - 55 tristearate , poloxamer F - 68 , and / or polyanhydroglucuronic 
mer is polyethylene oxide , chitosan , povidone ( PVP or acid . The hydrophilic polymer may be a polyethylene oxide , 
polyvinylpyrrolidone ) , or polyanhydroglucuronic acid . The a polysaccharide , a protein , an oxidized cellulose polymer , 
drug may be an anti - cancer compound . The anti - cancer polyanhydroglucuronic acid , a poloxomer , chitosan , or 
compound may be a chemotherapy or a chemotherapeutic providone ( PVP ) . In some embodiments , the implant further 
agent . In some embodiments , the chemotherapeutic is temo - 60 comprises lipase . The implant is configured for insertion into 
zolomide , paclitaxel , cetuximab , irinotecan , everolimus , car - a resection cavity . In some embodiments , the implant has 
boplatin , or docetaxel . The drug may be cisplatin , topotecan , been cured at temperatures of at least about 40° C . , 45° C . , 
bevacizumab , doxorubicin , everolimus , paclitaxel , irinote - 50° C . , 55° C . , 60° C . , 65° C . , 70° C . , 75º C . , 80° C . , 85° 
can , carboplatin , D - actinomycin , docetaxel , pitavastatin , C . , 90° C . , 95° C . , 100° C . , or up to 200° C . In some 
methotrexate , temozolomide , epirubicin , cetuximab , a cop - 65 embodiments , the implant has been sterilized by gamma 
per chelating agent , carmustine , a synthetic alkyl lysophos - radiation , ethylene oxide , or electron beam radiation . In 
pholipid , a bioactive sulfated saponin , steroid , or a statin . In some embodiments , the implant or wafer has been processed 
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by compression , hot - melt extrusion , injection molding , dry e taxel . The first composition may comprise at least a first 
powder coating , dipping , coating , spraying , hot - melt granu chemotherapeutic agent and a second chemotherapeutic 
lation , casting , an evaporation technology , or any combina - agent such as a combination of carboplatin and docetaxel . 
tion thereof . The implant may comprise : 0 . 1 - 50 % of the The hydrophobic agent may be a steroid such as choles 
drug , 5 - 95 % of the hydrophobic lipid or polymer , and about 5 terol . In other embodiments , the hydrophobic agent is a fatty 
3 - 50 % of the hydrophilic polymer or pore forming agent . In acid such as a saturated fatty acid . The fatty acid may have 
some embodiments , the implant is further defined as a 6 to 24 carbon atoms or 12 to 24 carbon atoms . A non 
bilayered implant or wafer , or a trilayered implant or wafer . limiting example of the fatty acid is stearic acid . In other 
In some embodiments , the implant allows for release of the embodiments , the hydrophobic agent is a glyceride such as 
drug over a period of at least 3 , 4 , 5 , 6 , 7 , 8 , 9 , 10 , 11 , 12 , 10 a mixture of monoglyceride , diglyceride , and triglyceride . 
13 , 14 , 15 , 16 , 17 , 18 , 19 , 20 , 21 , 22 , 23 , 24 , 25 , 26 , 27 , 28 , The glyceride mixture may predominately contain one or 
29 , or 30 or more days , or at least 1 , 2 , 3 , 4 , 5 , or 6 weeks , more diglycerides . In some embodiments , the glyceride is a 
or any range derivable therein . The implant may further glyceryl behenate . The first composition may comprise 
comprise a surfactant , a carbohydrate , a polyol , a protein , a glyceryl behenate , stearic acid , polyanhydroglucuronic acid , 
peptide , and / or an excipient . 15 and / or polyethylene oxide . The second composition may 
Another aspect of the present invention relates to a comprise polyethylene oxide , glycerol behenate , and / or cho 
method of treating a disease or traumatic injury in a mam - lesterol . The third composition may comprise stearic acid or 
malian subject , comprising administering into a resection glyceryl behenate and / or chitosan . 
cavity in the subject the implant of the present invention or In some embodiments , the subject is a human . The 
an described above , wherein the drug elution surface is 20 methods may further comprise removing part or all of a 
positioned proximal to the resection cavity , and , the further tumor from the subject via the resection cavity . In some 
layer or layers comprising the lipophilic backing layer embodiments , the tumor is cancerous . The tumor may be a 
and / or the hydrophobic coating are positioned distal and / or brain tumor such as a glioblastoma or glioblastoma multi 
lateral to the drug elution surface . The subject may be a forme . In some embodiments , the cancer is a metastatic 
mammal such as , e . g . , a human . The resection cavity may be 25 cancer . 
in the brain of the subject . The resection cavity may be in the The first layer may comprise temozolomide , stearic acid , 
spine , lung , neck , knee , back , a joint , bladder , or uterus . The lipase , cholesterol , glycerol behenate , poloxamer F - 68 , and / 
disease may be an inflammatory disease , pain , an infection , or polyanhydroglucuronic . The first composition , the second 
or inflammation . In some embodiments , the disease is a composition , and optionally the third composition may be 
cancer . The method may further comprise removing part or 30 comprised in a wafer or a tablet . The wafer or tablet may be 
all of a tumor from the subject via the resection cavity . In configured for insertion into the resection cavity . In some 
some embodiments , the tumor is cancerous . In some embodiments , the wafer or tablet further comprises an 
embodiments , the tumor is a brain tumor , a glioblastoma or antibiotic or an antimicrobial agent . In some embodiments , 
glioblastoma multiforme , or a high grade intrinsic brain the wafer or tablet does not contain dichloromethane ( meth 
tumor . The cancer may be a metastatic cancer . In some 35 ylene chloride ) , acetone , tetrahydrofuran , or ethyl acetate . 
embodiments , the surface of the resection cavity or at least The wafer or tablet may not contain an organic solvent . 
of the part the resection cavity is filled with a surgical glue The implant or wafer may further comprise an additional 
or a fibrin glue , e . g . , after wafer implantation . In some therapeutic agent such as an antibiotic , a statin , an anti 
embodiments , the resection cavity is filled with surgical glue fungal agent , an anti - viral agent , an anti - coagulant , a pain 
e . g . , after wafer implantation . The surgical glue may be , e . g . , 40 medication , an NSAID , or a steroid . The anti - cancer com 
DuraSeal® , Tiseal® or Eviseal® , or other similar surgical pound may be cisplatin , topotecan , bevacizumab , doxoru 
glue . In some embodiments , part of all of the implant is bicin , everolimus , paclitaxel , irinotecan , carboplatin , D - ac 
covered with a biocompatible , biodegradable surgical fabric tinomycin , docetaxel , pitavastatin , methotrexate , 
or Surgicel® temozolomide , epirubicin , cetuximab , a copper chelating 
Some aspects of the present invention may be understood 45 agent , carmustine , a synthetic alkyl lysophospholipid , a 
as a method of treating a cancer in a mammalian subject , bioactive sulfated saponin , or a statin . The lipid used herein 
comprising administering into a resection cavity in the may be glycerol behenate , a fatty acid , a cholesterol , a 
subject a pharmaceutically acceptable implant or wafer , glyceride , a hydrogenated vegetable oil , or tristearin . 
wherein the implant or wafer comprises : ( i ) a first compo - The hydrophilic polymer may be polyethylene oxide , 
sition comprising an anti - cancer compound , a lipid , and a 50 chitosan , povidone ( PVP ) , or polyanhydroglucuronic acid . 
hydrophilic polymer ; and ( ii ) a second composition com - The hydrophilic polymer may be a polyether such as a 
prising a hydrophobic agent ; wherein the second composi polyethylene oxide or polypropylene oxide . In some 
tion is located above or distal to the first composition in the embodiments , the hydrophilic polymer is a polyethylene 
resection cavity . oxide . The hydrophilic polymer may be a polysaccharide 
The method may further comprise administering a third 55 such as chitosan . In other embodiments , the hydrophilic 
composition into the resection cavity , wherein the third polymer comprises a mixture of a polyether and a polysac 
composition comprises a hydrophilic polymer . The third charide such as a mixture of polyethylene oxide and chito 
composition may also enhance the bioadhesiveness of the san . The hydrophilic polymer may be a polyethylene oxide , 
first composition or the second composition . In some a polysaccharide , a protein , an oxidized cellulose polymer , 
embodiments , first composition , the second composition , 60 polyanhydroglucuronic acid , a poloxomer , chitosan , or 
and any third composition are further defined as pharma - providone ( PVP ) . The implant or wafer may also further 
ceutical compositions and comprise an excipient . The first comprise a lipase . In some aspects , the surface of the 
composition may be formulated in the resection cavity resection cavity or at least of the part the resection cavity is 
between the second composition and the third composition . filled with a surgical glue . In some embodiments , the sur 
The anti - cancer compound may be a chemotherapy or a 65 gical glue is DuraSeal® , Tiseal® or Eviseal® . 
chemotherapeutic agent such as temozolomide , paclitaxel , Also contemplated are implant or wafer as described in 
cetuximab , irinotecan , everolimus , carboplatin , or doc - the above methods . The implant or wafer may be pharma 
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cologically acceptable and configured for insertion into a d . optionally one or more other pharmaceutical inactive 
resection cavity . The implant or wafer may be cured at ingredients ; and 
temperatures of at least about 40° C . , 45° C . , 50° C . , 55° C . , e . a hydrophobic second layer . 
60° C . , 65º C . . 70° C . , 75º C . , 80° C . , 85° C . , 90° C . , 950 The process may also be performed such that it does not 
C . , 100° C . , or up to 200° C . The implant or wafer may also 5 require an organic solvent . In some embodiments , the pro 
be processed by compression , hot - melt extrusion , injection cess comprises using a hot - melt extrusion , compression , 
molding , dry powder coating , hot - melt granulation , casting , injection molding , evaporation , hot - melt granulation , dry 
evaporation technologies , dipping , spraying , or any combi powder coating or the like . In some embodiments , the 
nation thereof . In some embodiments , the implant or wafer process comprises preparing a pharmaceutical composition 10 implant by : further comprises an excipient . a . dissolve or disperse the anti - cancer compound in mol In yet another aspect , the present disclosure includes ten liquid carrier ; pharmaceutical bilayered wafer implant composition com b . disperse or dissolve the hydrophilic polymers in the prising : a . one or more biologically active anti - cancer com molten composition ; 
pounds to treat malignant tumors present in the brain ; b . one 15 c . pour the molten mix into molds to form the implant ; and or more lipid components ; c . one or more water soluble d . cool into wafers ; or hydrophilic pore forming polymeric components ; d . option e . alternatively , cool , form granules pass through 60 mesh 
ally one or more other inactive pharmaceutical ingredients ; screen , compress into wafers or tablets and , cure at 
e . a hydrophobic second layer , located side - by - side with the elevated temperature for several hours . 
drug containing layer ; f bilayered compositions are then 20 The process may further relate to preparing tablet implant 
cured at elevated temperatures . compositions by compression . The process may further 
The compositions may contain one or more lipid compo - comprise process to prepare compositions that will have no 
nents in the drug layer , including : glycerol behenate , mono , significant influence on the pH of the surrounding biological 
di - and tri - glycerides , long chain fatty acids , cholesterols , fluid following surgical removal of the malignant tumor . The 
and the like . In some embodiments , the compositions com - 25 processes relate to the addition to the anti - cancer compound 
prise 0 . 1 - 50 % biologically active compounds , 20 - 95 % lipid present in the solid pharmaceutical implant compositions to 
component , about 5 - 50 % hydrophilic bioadhesive compo - also include antibiotics , antifungal agents , local anesthetics , 
nent and 0 - 50 % suitable additives to enhance processing of NSAIDS , statins , steroids , contraceptives , antivirals , and 
the wafer or to control the release of the active compound anti - cancer agents that do cross the blood - brain barrier . In 
from the implant . The pharmaceutical wafer implant or 30 some embodiments , the patient is a mammal such as a 
tablets composition may contain a biologically active com mammal . 
pound in sufficient concentrations to achieve a therapeutic In some embodiments , the composition may be sterilized 
level of the compound in a patient over a period of about one by ethylene oxide , gamma radiation , or electron beam 
week up to about six months . These biologically active radiation . The composition may further a lipase . The com 
compounds may include drugs to treat glioblastoma multi - 35 positions may also further comprise a poorly water soluble 
forme . In other embodiments , the biologically active com - or water insoluble hydrophobic second layer applied to one 
pounds may include drugs to treat a brain tumor such as a surface of the drug containing tablet or wafer . In some 
high grade intrinsic brain tumor . embodiments , the compositions may be implanted into a 
In some embodiments , the biologically active compounds patient ' s brain , immediately following the surgical removal 
can compounds alone or in combination to treat and / or cure 40 of the tumor . The composition may be used to provide 
malignant brain tumors to include cisplatin , topotecan , beva - unidirectional delivery of chemotherapeutic agents to the 
cizumab , doxorubicin , everolimus , paclitaxel , irinotecan , brain . The compositions may also be applied directly to the 
carboplatin , D - actinomycin , docetaxel , pitavastatin , metho - wall of the cavity in the brain following surgical removal of 
trexate , temozolomide , epirubicin , cetuximab , copper the tumor . The compositions may also be applied directly to 
chelating agents , carmustine , synthetic alkyl lysophospho - 45 the wall of the resection cavity in the brain followed by 
lipids , bioactive sulfated saponins statins and the like . The covering with Surgicel® knitted fabric , and / or Duraseal® , 
pharmaceutical solid dosage compositions may release the Evicel® , or Tisseel® following the surgical removal of the 
biologically active compound in the brain over a period of tumor . In one embodiment , the resection cavity is filled with 
about one week up to six months . Similarly , the composi - surgical glue . In some embodiments , the compositions also 
tions may further comprise one or more hydrophilic poly - 50 comprise a separate third layer comprising one or more 
mers comprising polyethylene ( oxide ) , chitosans , hydrophilic polymers where the final composition comprises 
poloxymers , polysaccharides , polyols , proteins , polyanhy - a drug containing layer sandwiched between the hydropho 
droglucuronic acid , peptides , providone ( PVP ) and the like . bic layer and a hydrophilic polymeric layer . 
In some embodiments , the compositions comprise one or In some aspects , an implant or wafer of the present 
more hydrophilic nonpolymer components comprising 55 invention may comprise temozolomide or other anti - cancer 
amino acids . The compositions may also comprise one or compound ( s ) . The implant or wafer comprising temozolo 
more inert excipients including surfactants , carbohydrates , mide or other anti - cancer compounds may be inserted into 
polyols , proteins , and / or other excipients having no signifi the resection cavity during the same surgical procedure 
cant effect on the pH of surrounding biological fluid at the and / or immediately after the tumor is removed . In some 
site of implantation of the wafer in the brain . 60 embodiments , an added advantage of the implant wafers 
In another aspect , the process of preparing bilayered solid provided in the present invention is that the patient begins 
dosage compositions for timed release biologically active their chemotherapy at the time of surgery . The bioadhesive 
anti - cancer compounds to treat and cure malignant tumors hydrophilic components in the implant may facilitate the 
comprising in one layer : surgeon applying the device to the wall of the cavity , which 
a . one or more biologically active compounds ; 65 can promote drug diffusion into the brain and not the 
b . one or more lipid components ; resection cavity fluid . The addition of a second hydrophobic 
c . one or more hydrophilic polymeric components ; layer to the top surface and / or a coating to desired non - drug 
Gifi 
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eluding sides of the implant can promote unidirectional drug reported to increase after surgery but then decline sharply , 
absorption into the tissue and decrease the release of drug particularly in the brain . In some embodiments , about 1 . 5 
into the spinal fluid present in the brain cavity . In contrast to 4 % , 1 , 1 . 5 , 2 , 2 . 5 , 3 , 3 . 5 , 4 , 4 . 5 , or 5 % or any range derivable 
methods of oral administration of temozolomide after a therein of polyethylene oxide may be particularly useful in 
surgery ( e . g . , to remove a glioblastoma multiforme tumor ) 5 implants or wafers of the present invention . 
involving a delay between the surgery and initiation of the As used herein the specification , “ a ” or “ an ” may mean 
temozolomide therapy , the use of an implant or wafer one or more . As used herein in the claim ( s ) , when used in 
comprising the temozolomide or another anti - cancer com conjunction with the word " comprising ” , the words “ a ” or pounds may reduce , minimize , or effectively eliminate the " an " may mean one or more than one . delay between removal of the tumor and initiation of the 10 The use of the term “ or ” in the claims is used to mean additional therapy . In some embodiments , utilizing local " and / or ” unless explicitly indicated to refer to alternatives delivery of the anti - cancer compounds by using implants in only or the alternatives are mutually exclusive , although the the brain , the systemic dose of this agent , when delivered 
disclosure supports a definition that refers to only alterna orally , may be reduced , which may also decrease the inci 
is tives and " and / or . ” As used herein " another ” may mean at dence of known systemic side effects . 
In some embodiments , a wafer or tablet of the present least a second or more . 
invention does not include organic solvents such as a polar Throughout this application , the term “ about ” is used to 
aprotic or polar protic solvents . Some non - limiting examples indicate that a value includes the inherent variation of error 
of organic solvents include alcohols , haloalkanes , ketones , for the device , the method being employed to determine the 
esters , and ethers of 12 or less carbon atoms such as ethanol , 20 value , or the variation that exists among the study subjects . 
dichloromethane ( or methylene chloride ) , acetone , tetrahy - Other objects , features and advantages of the present 
drofuran , or ethyl acetate . In some embodiments , a wafer or invention will become apparent from the following detailed 
tablet of the present invention may also not include any of description . It should be understood , however , that the 
the water insoluble polymers that are described in the U . S . detailed description and the specific examples , while indi 
Pat . No . 8 , 821 , 913 . cating preferred embodiments of the invention , are given by 
“ Unidirectional ” as used herein refers to the diffusion of way of illustration only , since various changes and modifi 
a therapeutic compound ( e . g . , anti - cancer compound , che cations within the spirit and scope of the invention will 
motherapeutic compound , etc . ) out of an implant or wafer of become apparent to those skilled in the art from this detailed 
the present invention . A “ backing ” layer and / or hydrophilic description . 
coating containing a hydrophobic material may reduce , 30 
minimize , or prevent the therapeutic compound from trav BRIEF DESCRIPTION OF THE DRAWINGS 
elling through a resection cavity towards the exterior surface 
of a subject ( e . g . , towards the skull or scalp of a human The following drawings form part of the present specifi 
patient ) . cation and are included to further demonstrate certain 
In some aspects , the implants or wafers use a hydrophobic 35 aspects of the present invention . The invention may be better 
agent that is layered distal to or onto the surface of the drug understood by reference to one or more of these drawings in 
containing layer to promote unidirectional absorption combination with the detailed description of specific 
through the wall of the cavity in the brain , following tumor embodiments presented herein . 
removal . The presence of an optional third hydrophilic layer FIG . 1 : Release from single layer wafers . Each of the 
added to the implant may promote adhesion of the implant 40 single layer wafers were tested with different PolyOx 303 
directly to the brain along the sides of the resection cavity . ( solid line and solid diamond , 0 % PolyOx 303 ; solid line and 
The drug containing layer would be " sandwiched ” between open square , 1 . 5 % PolyOx 303 ; dashed line and open 
the hydrophobic and adhesive layer . To further promote the diamond , 3 % PolyOx 303 ; dashed lines and solid diamond , 
unidirectional flow of the chemotherapeutic agent through 4 % PolyOx 303 ; and solid line and solid square , 5 % PolyOx 
the wall of the brain cavity , the implants of the present 45 303 ) 
invention may preferably be held in place with a covering of FIG . 2 : Release from coated bilayer wafers with different 
Surgicel® , a surgical knitted fabric , or a surgical glue such grades of PEO and different levels ( 0 - 3 % ) of PEO . ( solid 
as DuraSeal® , Tiseal® or Eviseal® . The surgical glue line and solid diamond , No PEO ; dashed line and solid cross , 
applied to the hydrophobic layer of the implant , may harden 1 . 5 % PolyOx N10 ; dashed line and open diamond , 1 . 5 % 
within seconds and may not only maintain adherence of the 50 PolyOx N12K , dashed line and solid diamond , 1 . 5 % PolyOx 
implant to the wall of the brain cavity , but may also help 303 ; solid line and solid diamond , 3 % PolyOx N10 ; solid 
prevent drug release from the sides of the implant into the line and open square , 3 % PolyOx N12K ; and solid line and 
brain cavity , thereby promoting the unidirectional absorp - solid square , 3 % PolyOx 303 ) . Release of acetaminophen 
tion of drug from the implant into the local environment of ( APAP ) from coated bi - layer ( bio - adhesive layer and drug 
the brain . 55 layer ) wafer was measured . The drug layer composition 
The hydrophilic polymers present in the drug containing included 5 % APAP , the above noted percent of PEO of 
layer of the implant may influence both the erosion and various grades , and glycerol behenate q . s . to 100 % , a total 
permeability of the implant . The curing of the wafer at of 200 mg including a bio - adhesive layer of 50 mg PEO 303 . 
elevated temperature can increase the adhesion amongst These compositions were used to investigate the percent of 
layers in the implant . Preferred hydrophilic polymers 60 PEO and grade of PEO on drug release from coated bi - layer 
include polyethylene oxide , chitosan , povidone ( PVP ) and wafer . Without the hydrophobic backing layer , portion of 
polyanhydroglucuronic acid . The lipids may be slowly bro - drug layer melted away during dip - coating process . As a 
ken down by enzymes in the lipase family , which are result , only 75 % drug was recovered at the end of the drug 
normally found throughout the human body . Additional release testing . As a result of these data , it may be concluded 
added low doses of lipase in the dosage form may also 65 that the higher the PEO molar mass , the faster the drug 
control the release rate of the active compound from the release is and the higher the percent of PEO , the faster the 
dosage form . Lipase levels in the blood serum have been drug release is . 
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FIG . 3 : Release from coated bilayers with different grades solid dosage forms since the lipids and hydrophilic polymers 
and levels ( 4 - 5 % ) of PEO . ( dashed line and solid cross , 4 % can have an insignificant , minimal , or no effect on the pH of 
PolyOx N10 ; solid line and open square , 4 % PolyOx N12K , the surrounding biological fluid at the site of implantation . 
solid line and solid square , 4 % PolyOx 303 ; dashed line and Thus , in accordance with one aspect , the present invention 
open diamond , 5 % PolyOx N10 ; dashed line and solid 5 includes pharmaceutical implant compositions as anti - can 
diamond , 5 % PolyOx N12K ; and solid line and solid dia - cer drug delivery systems comprising as ingredients : 
mond , 5 % PolyOx 303 ) . ( a ) anti - cancer compound ( s ) ; 
FIG . 4 : Release from single layered , bi - layer , and tri ( b ) lipid compound ( s ) ; 
layered wafers . Release of acetaminophen ( APAP ) from ( c ) hydrophilic polymeric agent ( s ) ; 
single ( drug layer ) , bi - layer ( drug layer + hydrophobic layer ) 10 ( d ) optional pharmaceutical additives or excipients 
and tri - layer ( bio - adhesive layer , drug layer , hydrophobic including enzymes or other active pharmaceutical 
layer and coating ) wafer . The composition of the wafer ingredients ; 
includes : ( 1 ) Drug layer composition : 5 % APAP , 3 % PEO ( e ) a hydrophobic top layer and / or coating ; and 
303 , and 92 % glycerol behenate , ( 2 ) Hydrophobic layer : 100 ( f ) an optional third layer comprising hydrophilic poly 
mg glycerol behenate , and ( 3 ) Bioadhesive layer : 50 mg 15 mer ( s ) . 
PolyOx 303 . The effect of the coating and bioadehsive layer The anti - cancer compounds in ( a ) ( above ) may include : 
on APAP release was analyzed . As can be seen in the figure , cisplatin , topotecan , bevacizumab , doxorubicin , everolimus , 
the coating slowed down drug release by reducing the total paclitaxel , irinotecan , carboplatin , D - actinomycin , doc 
surface area available for drug release . Without wishing to etaxel , pitavastatin , methotrexate , temozolomide , epirubi 
be bound by any theory , the presence of bio - adhesive layer 20 cin , cetuximab , copper chelating agents , carmustine , syn 
accelerated drug release may be based upon increased thetic alkyl lysophospholipids , bioactive sulfated saponins , 
facilitation the hydration of drug layer . statins and the like . The nonionic lipid compounds in ( b ) 
FIG . 5 : Effect of curing at 73° C . for 10 minutes on the ( above ) may include : glycerol behenate , fatty acid , choles 
release of acetaminophen ( APAP ) from tri - layer ( bio - adhe - terol , glycerides , hydrogenated vegetable oils , tristearin , 
sive layer , drug layer , hydrophobic layer and coating ) wafer . 25 stearic acid , and the like . The water soluble hydrophilic 
The drug composition includes : ( 1 ) Drug layer composition : polymeric pore forming agents included in the drug con 
5 % APAP , 3 % PEO 303 , and 92 % glycerol behenate , a total taining layer , ( c ) , above ) as well as polymers comprising the 
of 200 mg ; ( 2 ) Hydrophobic layer composition : 100 mg optional third layer in the implants , ( f ) , above ) , include : 
glycerol behenate ; and ( 3 ) Bio - adhesive layer composition : polyethylene oxides , polysaccharides , proteins , oxidized 
50 mg PolyOx 303 . The effects of curing on the APAP 30 cellulose polymers , polyanhydroglucuronic acid , poloxom 
release showed that the curing and uncured samples had ers , chitosan , providone ( PVP ) and the like . Temozolomide 
similar release profiles . is an alkalating agent that may be used , e . g . , to treat 
FIG . 6 : DSC Thermogram of APAP , compritol , their malignant primary brain tumors . Temozolomide is generally 
mixture prepared by physical blending , and their mixture 100 % bioavailable in the systemic bloodstream of the 
prepared using melt granulation . 35 patient when taken orally and is able to cross the blood - brain 
FIG . 7 : An embodiment of a multi - layered wafer . barrier , however the concentrations in the central nervous 
system have been reported to only be approximately 30 % of 
DESCRIPTION OF ILLUSTRATIVE plasma concentrations . Temozolomide has lipophilic prop 
EMBODIMENTS erties and is a low molecular weight molecule . This com 
40 pound typically must be present in the CNS in order for it to 
In some aspects , wafers or implants are provided that may be converted to the active metabolite . 
be used to deliver a therapeutic agent to a resection cavity in In some embodiments , a secondary therapeutic agent is 
the tissue of a subject , e . g . , after surgical removal of tissue . included in the implant or wafer in addition to the anti 
For example , the wafer or implant may be used to deliver a cancer agent . The implant wafer compositions may com 
chemotherapeutic agent to the brain of a subject after 45 prise an optional secondary therapeutic agents including , 
removal of a tumor from the brain of the subject . In some e . g . , one or more antibiotics , statins , anti - fungals , anti - virals , 
embodiments , the implant or wafer comprises multiple pain medications , contraceptives , NSAIDS and steroids , to 
layers that may promote release of the therapeutic agent into achieve simultaneous administration of the agents to a 
the tissue , which may result in an improved therapeutic cancer patient . Such agents may be included with the 
benefit . 50 anti - cancer compound in the wafer compositions of the 
In some aspects , a one or more anticancer compounds present compositions or may be administered to the patient 
may be included in a wafer or implant of the present in a separate wafer . 
invention ( e . g . , for the treatment glioblastoma multiforme ) . The present invention also provides , in some aspects , 
In some embodiments , the anticancer compound included in methods of preparation of the wafers . For example , the 
the wafer or implant is a compound that does not cross the 55 pharmaceutical wafer compositions of the present invention 
blood - brain barrier in sufficient amounts to exert a thera - may be processed by compression , hot - melt extrusion , injec 
peutic response when delivered by oral or parenteral routes . tion molding , dry powder coating , hot - melt granulation , 
Thus , in these embodiments , the wafer or implant can casting , evaporation technologies , dipping , spraying , or 
provide a particularly useful opportunity to deliver a thera - combinations of these methods . Elevated temperature curing 
peutic compound to or near to the site of surgery in the brain , 60 is utilized to promote adhesion of the layers in the wafer . 
where it would be otherwise difficult to deliver that com - In some aspects , implant wafers and methods provided 
pound due to the particular pharmacokinetics , etc . of the herein may be used to maintain therapeutic concentrations of 
anti - cancer compound . Other adjunct non - therapeutic com - the drug at the site of implantation following surgical 
pounds may be included in the formulations , including removal of the tumor , e . g . , from about 1 , 2 , 3 , 4 , 5 , 6 , 7 , 8 , 
absorption enhancing substances , antioxidants and other 65 9 , 10 weeks , or 1 , 2 , 3 , 4 , 5 , 6 months , or any range derivable 
functional excipients . In some embodiments , little or no therein . The particular rate of diffusion or release of the 
acidic byproducts are formed from the slow erosion of the active agent , therapeutic agent , or anticancer agent may be 
US 9 , 956 , 172 B2 
15 16 
varied or affected based the composition of the drug delivery arabinose . Some non - limiting examples of polysaccharides 
system ( e . g . , particular polymers included in the implant or which may be used include glycogen , amylose , amylopectin , 
capsule , ratio of hydrophilic and hydrophobic polymers arabinoxylan , cellulose , chitin or chitosan , or pectin . In 
included , etc . ) and the dose of the active moiety being some embodiments , the polysaccharide is chitin or chitosan . 
delivered . 5 In some embodiments , the wafer or implant may comprise 
A . Hydrophilic Compound or Polymer one or more pharmaceutical additives or excipients that aid 
A variety of hydrophilic compounds or polymers may be processing and can regulate the release of the active drug 
included in an implant or wafer of the present invention . For substance from the wafer . Such additives or excipients 
example , in some embodiments , the hydrophilic compound include , e . g . , biocompatible surfactants , lipase , lecithin , 
is polyanhydroglucuronic acid . This material is currently 10 polyols , proteins , enzymes , peptides and the like , and other 
used in surgery as a hemostatic agent to reduce blood clots suitable agents familiar to a person skilled in the art of 
and to promote wound healing . It is also an effective preparing solid pharmaceutical dosage forms . The presence 
antibacterial agent . Polyanhydroglucuronic acid is an oxi - of lipase in the solid dosage form , may aid in the metabolism 
dized cellulose polymer with a basic unit of polyanhydro - and elimination of fats and lipids at the implant site . The 
glucuronic acid . Related materials are described in U . S . Pat . 15 presence of absorption enhancing agents such as sodium 
No . 3 , 364 , 200 . Polyanhydroglucuronic acid is the base lauryl sulfate and the polysorbates may also be included in 
material in the Surgicel® knitted fabric product that has has the drug containing layer of the implant . 
been used in surgery , including neurosurgery . B . Hydrophobic Compounds or Agents 
In some aspects of the present disclosure , the composition In some embodiments , the composition of one or more of 
comprises a hydrophilic polymer . Hydrophilic polymers 20 the layers contains a hydrophobic compound or hydrophobic 
may contain polar or charged groups such that the polymer agent . These hydrophobic compounds may include steroids , 
is soluble in water or aqueous mixtures . In particular , the fatty acids , and / or glycerides . When a lipid is used in the 
hydrophilic polymers contain one or more groups , which wafer or capsule , it is anticipated that the lipid may be used 
can act as a hydrogen bond donor or acceptor or a charged in conjunction with or substituted for one or more the 
group such as a carboxylic acid group or an amine group . 25 hydrophobic compounds described herein ( e . g . a fatty acid 
Some non - limiting examples of hydrophilic polymers or glyceride may be included instead of the lipid ) . 
include : polyacrylamide , polyimines , polyacrylic acid , poly - Steroids are compounds which contain a four ring fused 
ethylene oxide , polypropylene oxide , polyvinyl alcohol , structure as shown below : 
polyvinylpyrrolidone , polyether , polymers of maleic anhy 
dride , polyelectrolytes such as polystyrenesulfonates , or 30 
other water soluble groups such as cucurbit [ n ] uril . 
In some embodiments , the hydrophilic polymer is a 
polyether . For examples , a polyether polymers that may be 
used in various embodiments include polyethylene oxide 
( also known as polyethylene glycol , PEG , or PEO ) and 35 
polypropylene oxide ( PPO ) . PEO is the polymeric form of 
ethylene glycol , while PPO is the polymeric form of pro 
pylene glycol . The formula of PEO and PPO , respectively , 
are shown below : also known as hexadecahydro - 1H - cyclopenta [ a ] phenan 
40 threne . The steroids described herein may have a hydroxy or H ( OCH2CH2 ) OH oxo substituted on carbon atom 3 and are commonly sub 
stituted with an alkyl group at one or more of carbon atoms 
H ( OCH CH2CH2 ) , OH 10 , 13 and 17 . In some embodiments , the hydroxy substi 
wherein the repeating unit , n , is an integer . In some aspects , tution at position 3 of the steroid is in the ß orientation . In 
the nomenclature used to describe PEO includes the average 45 some embodiments , the alkyl groups are at carbon atom 17 . 
molecular weight of the polymer ( e . g . PEO - 400 ; PEO - 500 , Without wishing to be bound by any theory , it is believed 
PEO - 600 , etc . ) In some embodiments , the molecular weight that steroids with any substituents on the ring , other orien 
of PEO ranges from about 100 , 000 to about 7 , 000 , 000 tations , salt forms and other known variations of the basic 
daltons ( e . g . , PEO 303 ) , more preferably from about 1 , 000 , ring may be used in the compositions described herein . 
000 to about 7 , 000 , 000 daltons . In some embodiments , the 50 Some non - limiting examples of steroids include cholesterol , 
molecular weight of the PEO is about le5 , 2 . 5e5 , 5e5 , 1e6 , androstenolone , androsterone , brassicasterol , calciferol , 
2e6 , 3e6 , 4e6 , 5e6 , 6e6 , 7e6 , 8e6 daltons , or any range campesterol , cholestanol , cholestenone , coprostene , corti 
derivable therein . As would be obvious to a person of skill s one , demosterol , diosgenin , dihydrocalciferol , ergosterol , 
in the art , the average molecular weight does not mean that epicholestanol , estrone , estradiol , fucosterol , hecogenin , 
any particular PEO or PPO molecule within the composition 55 hexahydrolumi sterol , lanosterol , lumisterol , pregnenolone , 
has the noted molecular weight but rather that the compo progesterone , oestrone , sarsasapogenin , sitosterol , smi 
sition as a whole has the average molecular weight corre - lagenin , spinastenol , stigmasterol , stigmastanol , testoster 
sponding to that value . In some embodiments , the PEO or one , tigogenin and tomatidine . In some embodiments , the 
PPO molecule can have one or both of the terminal hydrogen steroids used herein is cholesterol . 
atoms can be replaced with another group including but not 60 In other embodiments , the compositions of the present 
limited to an alkyl group ( e . g . a methyl group or an ethyl disclosure may include fatty acids and / or glycerides . Fatty 
group ) . acids are long chain alkyl groups with a carboxylic acid at 
In other embodiments , the composition comprises a one end . In some embodiments , alkyl group of the fatty acid 
hydrophilic polymer which is a natural biopolymer . The has from 6 to 24 carbon atoms . These fatty acids which do 
hydrophilic polymer may be a natural biopolymer such as , 65 not contain any double bonds are saturated fatty acids . Fatty 
e . g . , a polysaccharide . Polysaccharides are oligomers of acids may also contain one or more double bonds in the alkyl 
sugars such as , e . g . , glucose , fructose , galactose , xylose , and group . Fatty acids containing one or more double bonds are 
( II ) 
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unsaturated fatty acids . If double bonds are present in the C . Implant Characteristics and Production 
fatty acid , these double bonds may be in the cis orientation . In some embodiments , the multilayered wafer implants of 
The alkyl group may comprise 1 , 2 , or 3 double bonds . Some the present invention may weigh between about 50 mg and 
non - limiting examples of fatty acids include : butyric acid , 800 mg , more preferably about 100 - 400 mg . The diameter of 
caproic acid , caprylic acid , capric acid , lauric acid , myristic 5 the wafer may vary from about 0 . 25 - 3 centimeters , with one 
acid , palmitic acid , margaric acid , stearic acid , arachidic to two centimeters being more preferred . The thickness of 
acid , behenic acid , lignoceric acid , palmitoleic acid , oleic these wafers may vary from about 0 . 5 - 5 . 0 mm , with 0 . 75 
acid , elaidic acid , vaccenic acid , gondoic acid , erucic acid , mm to 2 . 0 mm being more preferred . The drug content may 
mead acid , linoleic acid , a - linoleic acid , stearidonic acid , depend upon the processing and physical and chemical 
y - linoleic acid , arachidonic acid , eicosapentaenoic acid , cid 10 properties of the drug , polymers and lipids as well as the compressibility and thermal stability . The potency of the docosahexaenoic acid , or nervonic acid . wafers may vary from about 0 . 1 % to 60 % , with about 5 - 30 % In other embodiments , the compositions of the present being more preferred . The shape of the wafer implants can disclosure may include glycerides . Glycerides comprise be prepared in a variety of configurations such as , e . g . , esters of the glycerol and one , two , or three fatty acids of the 15 circ ome 15 circular , square , rectangular or oblong , and the implants can 
described herein . As would be understood by a person of be cut or split in half or into smaller particles as desired by be cut o 
skill in the art , a monoglyceride is a glycerol esterified to one the neurosurgeon at the time of implantation . In addition , the 
fatty acid , a diglyceride is a glycerol esterified to two fatty wafers may have surfaces that are concave or convex . The 
acids , and a triglyceride is a glyceride esterified to three fatty wafers can be sterilized , e . g . , by the use of gamma radiation , 
acids . It is also contemplated that the glycerides may be 20 ethylene oxide , or electron beam radiation . Bilayered and 
substituted with one or more other groups such as an amino trilayered wafers can be prepared by compression on a tablet 
acid , choline , a phosphate group , an alkylamino , or any press or a Carver press . A melt granulated powder blend of 
combination of theses groups . the lipid and drug components are physically blended with 
The term " unit dose ” or “ dosage ” refers to physically hydrophilic polymer for the drug containing layer and may 
discrete units suitable for use in a subject , each unit con - 25 be first added to the die , followed by the wax or lipid used 
taining a predetermined quantity of the therapeutic compo - as the top layer in the implant . The compressed wafer may 
sition calculated to produce the desired responses discussed then be heated at elevated temperatures of about 65° C . for 
above in association with its administration , i . e . , the appro - 2 - 4 hours or 73° C . for 10 minutes or a temperature between 
priate route and treatment regimen . The quantity to be the two . The curing temperature should be a few degrees 
administered , both according to number of treatments and 30 below the melting point of the hydrophobic retardant , to 
unit dose , depends on the effect desired . The actual dosage adhere the hydrophobic layer to the drug containing layer . 
amount of a composition of the present embodiments admin - Alternately , in some embodiments , for the three layered 
istered to a patient or subject can be determined by physical wafer , the first component that is present in the die is the 
and physiological factors , such as body weight , the age , hydrophilic polymer followed by the powder blend contain 
health , and sex of the subject , the type of disease being 35 ing the chemotherapeutic agent containing layer and finally 
treated , the extent of disease penetration , previous or con - the hydrophobic powder is added . The compressed wafer 
current therapeutic interventions , idiopathy of the patient , may then be heat treated as described above . 
the route of administration , and the potency , stability , and Additionally , a hydrophobic coating may be applied 
toxicity of the particular therapeutic substance . In other through a dipping , spraying , or similar technique to further 
non - limiting examples , a dose may also comprise from 40 promote unidirectionality and slow drug release . In some 
about 1 microgram / kg / body weight , about 5 microgram / kg embodiments , the coating covers the wafers on all or sub 
body weight , about 10 microgram / kg / body weight , about 50 stantially all sides where drug release is non - desirable . In 
microgram / kg / body weight , about 100 microgram / kg / body some embodiments , the bioadhesive layer is left mostly or 
weight , about 200 microgram / kg / body weight , about 350 completely uncoated , and the backing and sides are covered 
microgram / kg / body weight , about 500 microgram / kg / body 45 with the hydrophobic coating . 
weight , about 1 milligram / kg / body weight , about 5 milli - In some embodiments , the hydrophilic polymeric layer be 
gram / kg / body weight , about 10 milligram / kg / body weight , prepared by hot melt extrusion . A molten dispersion com 
about 50 milligram / kg / body weight , about 100 milligram / prising the lipid , hydrophilic polymer , chemotherapeutic 
kg / body weight , about 200 milligram / kg / body weight , about agent and other optional ingredients may then applied to the 
350 milligram / kg / body weight , about 500 milligram / kg / 50 film and allowed to cool . The final layer of molten lipid or 
body weight , to about 1000 milligram / kg / body weight or wax may then be applied . The resulting film may then be cut 
more per administration , and any range derivable therein . In into wafers of desired dimensions . The resulting wafers may 
non - limiting examples of a derivable range from the num - then be cured at elevated temperature for up to about 4 
bers listed herein , a range of about 5 milligram / kg / body hours . For example , the resulting wafer is cured for a time 
weight to about 100 milligram / kg / body weight , about 5 55 period from about 5 minutes to about 4 hours , or from about 
microgram / kg / body weight to about 500 milligram / kg / body 2 hours to about 4 hours . 
weight , etc . , can be administered , based on the numbers D . Indications 
described above . The practitioner responsible for adminis - In some preferred embodiments , an implant is applied to 
tration will , in any event , determine the concentration of a resection cavity ( e . g . , in the brain ) after surgical removal 
active ingredient ( s ) in a composition and appropriate dose ( s ) 60 of a cancerous tissue . In other embodiments , the implant 
for the individual subject . In certain embodiments , the may be applied to a resection cavity ( e . g . , in the brain or 
compositions and methods of the present embodiments other portion of the body ) after removal of a non - cancerous 
involve administration of an implant in a resection cavity as tissue . 
described herein in combination with a second or additional A variety of cancers may be treated using an implant of 
therapy . Such therapy can be applied in the treatment of any 65 the present invention . A tumor that is removed from the 
disease that is responsive to CDC . For example , the disease brain of a subject ( e . g . , a human patient ) may be cancerous , 
may be cancer . precancerous , or benign . In some embodiments , the tumor is 
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cancerous . The tumor in the brain may have originated in the noma ; inflammatory carcinoma ; paget ' s disease , mammary ; 
brain of the subject ( e . g . , a brain cancer ) or the tumor may acinar cell carcinoma ; adenosquamous carcinoma ; adeno 
have originated in a different part of the body ( e . g . , a carcinoma w / squamous metaplasia ; thymoma , malignant ; 
metastatic cancer that has originated in some other part of ovarian stromal tumor , malignant ; thecoma , malignant ; 
the body but has travelled to the brain ) . Tumors for which 5 granulosa cell tumor , malignant ; androblastoma , malignant ; 
the present treatment methods are useful include any malig - Sertoli cell carcinoma ; leydig cell tumor , malignant ; lipid 
nant cell type , such as those found in a solid tumor or a cell tumor , malignant ; paraganglioma , malignant ; extra 
hematological tumor . Exemplary solid tumors can include , mammary paraganglioma , malignant ; pheochromocytoma ; 
but are not limited to , a tumor of an organ selected from the glomangiosarcoma ; malignant melanoma ; amelanotic mela 
group consisting of pancreas , colon , cecum , stomach , brain , 10 noma ; superficial spreading melanoma ; malignant mela 
head , neck , ovary , kidney , larynx , sarcoma , lung , bladder , noma in giant pigmented nevus ; epithelioid cell melanoma ; 
melanoma , prostate , and breast . Exemplary hematological blue nevus , malignant ; sarcoma ; fibrosarcoma ; fibrous his 
tumors include tumors of the bone marrow , T or B cell tiocytoma , malignant ; myxosarcoma ; liposarcoma ; leiomyo 
malignancies , leukemias , lymphomas , blastomas , myelo - sarcoma ; rhabdomyosarcoma ; embryonal rhabdomyosar 
mas , and the like . Further examples of cancers that may be 15 coma ; alveolar rhabdomyosarcoma ; stromal sarcoma ; mixed 
treated using the methods provided herein include , but are tumor , malignant ; mullerian mixed tumor ; nephroblastoma ; 
not limited to , carcinoma , lymphoma , blastoma , sarcoma , hepatoblastoma ; carcinosarcoma ; mesenchymoma , malig 
leukemia , squamous cell cancer , lung cancer ( including nant ; brenner tumor , malignant ; phyllodes tumor , malignant ; 
small - cell lung cancer , non - small cell lung cancer , adeno - synovial sarcoma ; mesothelioma , malignant ; dysgermi 
carcinoma of the lung , and squamous carcinoma of the 20 noma ; embryonal carcinoma ; teratoma , malignant ; struma 
lung ) , cancer of the peritoneum , hepatocellular cancer , gas - ovarii , malignant ; choriocarcinoma ; mesonephroma , malig 
tric or stomach cancer ( including gastrointestinal cancer and nant ; hemangiosarcoma ; hemangioendothelioma , malig 
gastrointestinal stromal cancer ) , pancreatic cancer , glioblas - nant ; kaposi ' s sarcoma ; hemangiopericytoma , malignant ; 
toma , cervical cancer , ovarian cancer , liver cancer , bladder lymphangiosarcoma ; osteosarcoma ; juxtacortical osteosar 
cancer , breast cancer , colon cancer , colorectal cancer , endo - 25 coma ; chondrosarcoma ; chondroblastoma , malignant ; mes 
metrial or uterine carcinoma , salivary gland carcinoma , enchymal chondrosarcoma ; giant cell tumor of bone ; 
kidney or renal cancer , prostate cancer , vulval cancer , thy - ewing ' s sarcoma ; odontogenic tumor , malignant ; ameloblas 
roid cancer , various types of head and neck cancer , mela tic odontosarcoma ; ameloblastoma , malignant ; ameloblastic 
noma , superficial spreading melanoma , lentigo malignant fibrosarcoma ; pinealoma , malignant ; chordoma ; glioma , 
melanoma , acral lentiginous melanomas , nodular melano - 30 malignant ; ependymoma ; astrocytoma ; protoplasmic astro 
mas , as well as B - cell lymphoma ( including low grade ) cytoma ; fibrillary astrocytoma ; astroblastoma ; glioblastoma ; 
follicular non - Hodgkin ' s lymphoma ( NHL ) ; small lympho - oligodendroglioma ; oligodendroblastoma ; primitive neu 
cytic ( SL ) NHL ; intermediate grade / follicular NHL ; roectodermal ; cerebellar sarcoma ; ganglioneuroblastoma ; 
intermediate grade diffuse NHL ; high grade immunoblastic neuroblastoma ; retinoblastoma ; olfactory neurogenic tumor ; 
NHL ; high grade lymphoblastic NHL ; high grade small 35 meningioma , malignant ; neurofibrosarcoma ; neurilem 
non - cleaved cell NHL , bulky disease NHL ; mantle cell moma , malignant ; granular cell tumor , malignant ; malignant 
lymphoma ; AIDS - related lymphoma ; and Waldenstrom ' s lymphoma ; hodgkin ' s disease ; hodgkin ' s ; paragranuloma ; 
macroglobulinemia ) , chronic lymphocytic leukemia ( CLL ) , malignant lymphoma , small lymphocytic ; malignant lym 
acute lymphoblastic leukemia ( ALL ) , Hairy cell leukemia , phoma , large cell , diffuse ; malignant lymphoma , follicular ; 
multiple myeloma , acute myeloid leukemia ( AML ) and 40 mycosis fungoides ; other specified non - hodgkin ' s lympho 
chronic myeloblastic leukemia . mas ; malignant histiocytosis ; multiple myeloma ; mast cell 
The cancer may specifically be of the following histo - sarcoma ; immunoproliferative small intestinal disease ; leu 
logical type , though it is not limited to these : neoplasm , kemia ; lymphoid leukemia ; plasma cell leukemia ; erythro 
malignant ; carcinoma ; carcinoma , undifferentiated ; giant leukemia ; lymphosarcoma cell leukemia ; myeloid leukemia ; 
and spindle cell carcinoma ; small cell carcinoma ; papillary 45 basophilic leukemia ; eosinophilic leukemia ; monocytic leu 
carcinoma ; squamous cell carcinoma ; lymphoepithelial car - kemia ; mast cell leukemia ; megakaryoblastic leukemia ; 
cinoma ; basal cell carcinoma ; pilomatrix carcinoma ; transi - myeloid sarcoma ; and hairy cell leukemia . 
tional cell carcinoma ; papillary transitional cell carcinoma ; The methods and compositions , including combination 
adenocarcinoma ; gastrinoma , malignant ; cholangiocarci - therapies , may enhance the therapeutic or protective effect , 
noma ; hepatocellular carcinoma ; combined hepatocellular 50 and / or increase the therapeutic effect of another anti - cancer 
carcinoma and cholangiocarcinoma ; trabecular adenocarci or anti - hyperproliferative therapy . Therapeutic and prophy 
noma ; adenoid cystic carcinoma ; adenocarcinoma in lactic methods and compositions can be provided in a 
adenomatous polyp ; adenocarcinoma , familial polyposis combined amount effective to achieve the desired effect , 
coli ; solid carcinoma ; carcinoid tumor , malignant ; bran - such as the killing of a cancer cell and / or the inhibition of 
chiolo - alveolar adenocarcinoma ; papillary adenocarcinoma ; 55 cellular hyper proliferation . This process may involve 
chromophobe carcinoma ; acidophil carcinoma ; oxyphilic administering a polypeptide or antibody and a second 
adenocarcinoma ; basophil carcinoma ; clear cell adenocar therapy . The second therapy may or may not have a direct 
cinoma ; granular cell carcinoma ; follicular adenocarcinoma ; cytotoxic effect . For example , the second therapy may be an 
papillary and follicular adenocarcinoma ; nonencapsulating agent that upregulates the immune system without having a 
sclerosing carcinoma ; adrenal cortical carcinoma ; endo - 60 direct cytotoxic effect . A tissue , tumor , or cell can be 
metroid carcinoma ; skin appendage carcinoma ; apocrine exposed to one or more compositions or pharmacological 
adenocarcinoma ; sebaceous adenocarcinoma ; ceruminous formulation ( s ) comprising one or more of the agents ( e . g . , a 
adenocarcinoma ; mucoepidermoid carcinoma ; cystadeno - polypeptide or an anti - cancer agent ) , or by exposing the 
carcinoma ; papillary cystadenocarcinoma ; papillary serous tissue , tumor , and / or cell with two or more distinct compo 
cystadenocarcinoma ; mucinous cystadenocarcinoma ; muci - 65 sitions or formulations , wherein one composition provides 
nous adenocarcinoma ; signet ring cell carcinoma ; infiltrat - 1 ) a polypeptide or antibody , 2 ) an anti - cancer agent , or 3 ) 
ing duct carcinoma ; medullary carcinoma ; lobular carci - both a polypeptide or antibody and an anti - cancer agent . 
21 
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Also , it is contemplated that such a combination therapy can drug wafer implant comprising a lipid and a hydrophobic 
be used in conjunction with chemotherapy , radiotherapy , polymer ) . The drug may be a chemotherapeutic . It is envi 
surgical therapy , or immunotherapy . sioned that virtually any chemotherapy or chemotherapeutic 
The terms “ contacted ” and “ exposed , ” when applied to a agent known may be included in an implant ( e . g . , a drug 
cell , are used herein to describe the process by which a 5 wafer implant ) or used in various embodiments of the 
therapeutic polypeptide or antibody and a chemotherapeutic present invention . In some embodiments , the chemothera 
or radio therapeutic agent are delivered to a target cell or are peutic agent may be included in a drug wafer implant to 
placed in direct juxtaposition with the target cell . To achieve achieve a local concentration in the brain ( e . g . , near the 
cell killing , for example , both agents are delivered to a cell injection site ) that is significantly higher than the systemic 
in a combined amount effective to kill the cell or prevent it it 10 concentration that one would typically be able to achieve by 
from dividing . systemic administration of the chemotherapeutic agent . 
E . Combination Therapies Alternately , an implant in a resection cavity as described herein may be used in combination with administration or a An implant in a resection cavity as described herein may 
be administered before , during , after , or in various combi chemotherapy agent or other therapy as described herein . 
nations relative to an anti - cancer treatment . The administra - 15 The term " chemotherapy ” refers to the use of drugs to 
treat cancer . A “ chemotherapeutic agent ” is used to connote tions may be in intervals ranging from concurrently to a compound or composition that is administered in the minutes to days to weeks . In embodiments where an implant 
in a resection cavity as described herein is provided to a treatment of cancer . These agents or drugs are categorized 
patient separately from an anti - cancer agent , one would by their mode of activity within a cell , for example , whether 
generally ensure that a significant period of time did not 20 not 20 and at what stage they affect the cell cycle . Alternatively , an 
expire between the time of each delivery , such that the two agent may be characterized based on its ability to directly 
cross - link DNA , to intercalate into DNA , or to induce compounds would still be able to exert an advantageously 
chromosomal and mitotic aberrations by affecting nucleic combined effect on the patient . In such instances , it is 
contemplated that one may provide a patient with the acid synthesis . 
polypeptide and the anti - cancer therapy within about 12 to 25 out 1 to 25 Examples of chemotherapeutic agents include alkylating 
24 or 72 h of each other and , more particularly , within about agents , such as thiotepa and cyclosphosphamide ; alkyl sul 
6 - 12 h of each other . In some situations it may be desirable fonates , such as busulfan , improsulfan , and piposulfan ; aziridines , such as benzodopa , carboquone , meturedopa , and to extend the time period for treatment significantly where uredopa ; ethylenimines and methylamelamines , including several days ( 2 , 3 , 4 , 5 , 6 , or 7 ) to several weeks ( 1 , 2 , 3 , 4 , 
5 , 6 , 7 , or 8 ) lapse between respective administrations . " 30 altretamine , triethylenemelamine , trietylenephosphoramide , 
In certain embodiments , a course of treatment will last triethiylenethiophosphoramide , and trimethylolomelamine ; 
1 - 90 days or more ( this range includes intervening days ) . It acetogenins ( especially bullatacin and bullatacinone ) ; a camptothecin ( including the synthetic analogue topotecan ) ; is contemplated that one agent may be given on any day of 
day 1 to day 90 ( this range includes intervening days ) or any bryostatin ; callystatin ; CC - 1065 ( including its adozelesin , 
combination thereof , and another agent is given on any day 35 carzelesin and bizelesin synthetic analogues ) ; cryptophycins 
of day 1 to day 90 ( this range includes intervening days ) or ( particularly cryptophycin 1 and cryptophycin 8 ) ; dolastatin ; 
any combination thereof . Within a single day ( 24 - hour duocarmycin ( including the synthetic analogues , KW - 2189 
period ) , the patient may be given one or multiple adminis and CB1 - TM1 ) ; eleutherobin ; pancratistatin ; a sarcodictyin ; 
trations of the agent ( s ) . Moreover , after a course of treat spongistatin ; nitrogen mustards , such as chlorambucil , chlo 
ment , it is contemplated that there is a period of time at 40 f time at 40 rnaphazine , cholophosphamide , estramustine , ifosfamide , 
which no anti - cancer treatment is administered . This time mechlorethamine , mechlorethamine oxide hydrochloride , 
period may last 1 - 7 days , and / or 1 - 5 weeks , and / or 1 - 12 melphalan , novembichin , phenesterine , prednimustine , tro 
months or more ( this such range includes intervening days ) , fosfamide , and uracil mustard ; nitrosureas , such as carmus 
depending on the condition of the patient , such as their tine , chlorozotocin , fotemustine , lomustine , nimustine , and 
prognosis , strength , health , etc . It is expected that the 45 the 45 ranimnustine ; antibiotics , such as the enediyne antibiotics 
treatment cycles would be repeated as necessary . ( e . g . , calicheamicin , especially calicheamicin gammall and 
Various combinations may be employed . For the example calicheamicin omegall ) ; dynemicin , including dynemicin 
below a polypeptide or antibody is “ A ” and an anti - cancer A ; bisphosphonates , such as clodronate ; an esperamicin ; as well as neocarzinostatin chromophore and related chro therapy is “ B ” : 50 moprotein enediyne antiobiotic chromophores , aclacino 
mysins , actinomycin , authrarnycin , azaserine , bleomycins , 
A / B / AB / A / BB / B / AA / A / BA / B / BB / A / AA / B / B / BB / A / B / B cactinomycin , carabicin , carminomycin , carzinophilin , 
chromomycinis , dactinomycin , daunorubicin , detorubicin , 
B / B / B / A B / B / A / B A / A / B / B A / B / A / BA / B / B / AB / B / A / A 6 - diazo - 5 - oxo - L - norleucine , doxorubicin ( including mor 
B / A / B / A B / A / A / B A / A / A / BB / A / A / AA / B / A / AA / A / B / A 55 pholino - doxorubicin , cyanomorpholino - doxorubicin , 2 - pyr rolino - doxorubicin and deoxydoxorubicin ) , epirubicin , eso 
Administration of any implant in a resection cavity as rubicin , idarubicin , marcellomycin , mitomycins , such as 
described herein or therapy of the present embodiments to a mitomycin C , mycophenolic acid , nogalarnycin , olivomy 
patient will follow general protocols for the administration cins , peplomycin , potfiromycin , puromycin , quelamycin , 
of such compounds , taking into account the toxicity , if any , 60 rodorubicin , streptonigrin , streptozocin , tubercidin , uben 
of the agents . Therefore , in some embodiments there is a imex , zinostatin , and zorubicin ; anti - metabolites , such as 
step of monitoring toxicity that is attributable to combina - methotrexate and 5 - fluorouracil ( 5 - FU ) ; folic acid ana 
tion therapy . logues , such as denopterin , pteropterin , and trimetrexate ; 
A . Chemotherapy purine analogs , such as fludarabine , 6 - mercaptopurine , thia 
A wide variety of chemotherapeutic agents may be used 65 miprine , and thioguanine ; pyrimidine analogs , such as ancit 
in accordance with the present embodiments . For example , abine , azacitidine , 6 - azauridine , carmofur , cytarabine , dide 
a chemotherapeutic may be comprised in an implant ( e . g . , a oxyuridine , doxifluridine , enocitabine , and floxuridine ; 
24 
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androgens , such as calusterone , dromostanolone propionate , on the majority of other cells . Many tumor markers exist and 
epitiostanol , mepitiostane , and testolactone ; anti - adrenals , any of these may be suitable for targeting in the context of 
such as mitotane and trilostane ; folic acid replenisher , such the present embodiments . Common tumor markers include 
as frolinic acid ; aceglatone ; aldophosphamide glycoside ; CD20 , carcinoembryonic antigen , tyrosinase ( p97 ) , gp68 , 
aminolevulinic acid ; eniluracil ; amsacrine ; bestrabucil ; 5 TAG - 72 , HMFG , Sialyl Lewis Antigen , MucA , MucB , 
bisantrene ; edatraxate ; defofamine ; demecolcine ; diazi - PLAP , laminin receptor , erb B , and p155 . An alternative 
quone ; elformithine ; elliptinium acetate ; an epothilone ; eto aspect of immunotherapy is to combine anticancer effects 
glucid ; gallium nitrate ; hydroxyurea ; lentinan ; lonidainine ; with immune stimulatory effects . Immune stimulating mol 
maytansinoids , such as maytansine and ansamitocins ; mito ecules also exist including : cytokines , such as IL - 2 , IL - 4 , 
guazone ; mitoxantrone ; mopidanmol ; nitraerine ; pentosta - 10 IL - 12 , GM - CSF , gamma - IFN , chemokines , such as MIP - 1 , 
tin ; phenamet ; pirarubicin ; losoxantrone ; podophyllinic MCP - 1 , IL - 8 , and growth factors , such as FLT3 ligand . 
acid ; 2 - ethylhydrazide ; procarbazine ; PSKpolysaccharide Examples of immunotherapies currently under investiga 
complex ; razoxane ; rhizoxin ; sizofiran ; spirogermanium ; tion or in use are immune adjuvants , e . g . , Mycobacterium 
tenuazonic acid ; triaziquone ; 2 , 2 ' , 2 " - trichlorotriethylamine ; bovis , Plasmodium falciparum , dinitrochlorobenzene , and 
trichothecenes ( especially T - 2 toxin , verracurin A , roridin A 15 aromatic compounds ( U . S . Pat . Nos . 5 , 801 , 005 and 5 , 739 , 
and anguidine ) ; urethan ; vindesine ; dacarbazine ; manno 169 ; Hui and Hashimoto , 1998 ; Christodoulides et al . , 
mustine ; mitobronitol ; mitolactol ; pipobroman ; gacytosine ; 1998 ) ; cytokine therapy , e . g . , interferons a , b , and y , IL - 1 , 
arabinoside ( " Ara - C ” ) ; cyclophosphamide ; taxoids , e . g . , GM - CSF , and TNF ( Bukowski et al . , 1998 ; Davidson et al . , 
paclitaxel and docetaxel gemcitabine ; 6 - thioguanine ; mer - 1998 ; Hellstrand et al . , 1998 ) ; gene therapy , e . g . , TNF , IL - 1 , 
captopurine ; platinum coordination complexes , such as cis - 20 IL - 2 , and p53 ( Qin et al . , 1998 ; Austin - Ward and Villaseca , 
platin , oxaliplatin , and carboplatin ; vinblastine ; platinum ; 1998 ; U . S . Pat . Nos . 5 , 830 , 880 and 5 , 846 , 945 ) ; and mono 
etoposide ( VP - 16 ) ; ifosfamide ; mitoxantrone ; vincristine ; clonal antibodies , e . g . , anti - CD20 , anti - ganglioside GM2 ,
vinorelbine ; novantrone ; teniposide ; edatrexate ; daunomy - and anti - p185 ( Hollander , 2012 ; Hanibuchi et al . , 1998 ; U . S . 
cin ; aminopterin ; xeloda ; ibandronate ; irinotecan ( e . g . , CPT - Pat . No . 5 , 824 , 311 ) . It is contemplated that one or more 
11 ) ; topoisomerase inhibitor RFS 2000 ; difluorometlhylor - 25 anti - cancer therapies may be employed with the antibody 
nithine ( DMFO ) ; retinoids , such as retinoic acid ; therapies described herein . 
capecitabine ; carboplatin , procarbazine , plicomycin , gem D . Surgery 
citabien , navelbine , farnesyl - protein transferase inhibitors , Approximately 60 % of persons with cancer will undergo 
transplatinum , and pharmaceutically acceptable salts , acids , surgery of some type , which includes preventative , diagnos 
or derivatives of any of the above . 30 tic or staging , curative , and palliative surgery . Curative 
B . Radiotherapy surgery includes resection in which all or part of cancerous 
Other factors that cause DNA damage and have been used tissue is physically removed , excised , and / or destroyed and 
extensively include what are commonly known as y - rays , may be used in conjunction with other therapies , such as the 
X - rays , and / or the directed delivery of radioisotopes to treatment of the present embodiments , chemotherapy , radio 
tumor cells . Other forms of DNA damaging factors are also 35 therapy , hormonal therapy , gene therapy , immunotherapy , 
contemplated , such as microwaves , proton beam irradiation and / or alternative therapies . Tumor resection refers to physi 
( U . S . Pat . Nos . 5 , 760 , 395 and 4 , 870 , 287 ) , and UV - irradia - cal removal of at least part of a tumor . In addition to tumor 
tion . It is most likely that all of these factors affect a broad resection , treatment by surgery includes laser surgery , cryo 
range of damage on DNA , on the precursors of DNA , on the surgery , electrosurgery , and microscopically - controlled sur 
replication and repair of DNA , and on the assembly and 40 gery ( Mohs ' surgery ) . 
maintenance of chromosomes . Dosage ranges for X - rays Upon excision of part or all of cancerous cells , tissue , or 
range from daily doses of 50 to 200 roentgens for prolonged tumor , a cavity may be formed in the body . Treatment may 
periods of time ( 3 to 4 wk ) , to single doses of 2000 to 6000 be accomplished by perfusion , direct injection , or local 
roentgens . Dosage ranges for radioisotopes vary widely , and application of the area with an additional anti - cancer 
depend on the half - life of the isotope , the strength and type 45 therapy . Such treatment may be repeated , for example , every 
of radiation emitted , and the uptake by the neoplastic cells . 1 , 2 , 3 , 4 , 5 , 6 , or 7 days , or every 1 , 2 , 3 , 4 , and 5 weeks 
C . Immunotherapy or every 1 , 2 , 3 , 4 , 5 , 6 , 7 , 8 , 9 , 10 , 11 , or 12 months . These 
The skilled artisan will understand that immunotherapies treatments may be of varying dosages as well . 
may be used in combination or in conjunction with methods E . Other Agents 
of the embodiments . In the context of cancer treatment , 50 It is contemplated that other agents may be included in a 
immunotherapeutics , generally , rely on the use of immune drug wafer implant or used in combination with certain 
effector cells and molecules to target and suppress immune aspects of the present embodiments to improve the thera 
cells . Blinatumomab ( Blincyto® ) is such an example . peutic efficacy of treatment . These additional agents include 
Checkpoint inhibitors , such as , for example , ipilumimab , are agents that affect the upregulation of cell surface receptors 
another such example . The immune effector may be , for 55 and GAP junctions , cytostatic and differentiation agents , 
example , an antibody specific for some marker on the inhibitors of cell adhesion , agents that increase the sensitiv 
surface of a tumor cell . The antibody alone may serve as an ity of the hyperproliferative cells to apoptotic inducers , or 
effector of therapy or it may recruit other cells to actually other biological agents . Increases in intercellular signaling 
affect cell killing . The antibody also may be conjugated to a by elevating the number of GAP junctions may increase the 
drug or toxin ( chemotherapeutic , radionuclide , ricin A chain , 60 anti - hyperproliferative effects on the neighboring hyperpro 
cholera toxin , pertussis toxin , etc . ) and serve merely as a liferative cell population . In other embodiments , cytostatic 
targeting agent . Alternatively , the effector may be a lym - or differentiation agents can be used in combination with 
phocyte carrying a surface molecule that interacts , either certain aspects of the present embodiments to improve the 
directly or indirectly , with a tumor cell target . Various anti - hyperproliferative efficacy of the treatments . Inhibitors 
effector cells include cytotoxic T cells and NK cells . 65 of cell adhesion are contemplated to improve the efficacy of 
In one aspect of immunotherapy , the tumor cell must bear the present embodiments . Examples of cell adhesion inhibi 
some marker that is amenable to targeting , i . e . , is not present tors are focal adhesion kinase ( FAKS ) inhibitors and Lov 
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astatin . It is further contemplated that other agents that The components for Layer 2 are first passed through a 60 
increase the sensitivity of a hyperproliferative cell to apop mesh screen to remove lumps and then blended in a twin 
tosis , such as the antibody c225 , could be used in combi shell blender for 5 minutes . The three layered wafer is 
nation with certain aspects of the present embodiments to compressed and used a described previously . These tech 
improve the treatment efficacy . 5 nologies and methods are familiar to a person of ordinary 
II . Kits skill in the art . A further embodiment of the present invention provides a Certain aspects of the present invention may provide kits , bilayered wafer implant composition comprises the follow such as therapeutic kits . For example , a kit may comprise ing ingredients : one or more pharmaceutical composition as described herein 
and optionally instructions for their use . Kits may also 
comprise one or more devices for accomplishing adminis Layer 1 . 85 % 
tration of such compositions . For example , a subject kit may carboplatin 7 . 5 % 
docetaxel 12 . 5 % comprise a pharmaceutical composition and wafer or glycerol behenate 43 % 
implant for accomplishing administration of a therapeutic 15 polyethylene oxide 1M 37 % 
agent into a tissue in a subject , e . g . , a brain tissue in a Layer 2 . Stearic Acid 15 % 
resection cavity in subject . 
Kits may comprise a container with a label . Suitable The components of Layer 1 are added first to the die in the 
containers include , for example , bottles , vials , and test tubes . tablet press , followed by the stearic acid . These wafers were 
The containers may be formed from a variety of materials , 20 compressed and then heated at 68° C . for 3 hours . 
such as glass or plastic . The container may hold a compo A further embodiment of the present invention for the 
sition that includes a polypeptide that is effective for thera manufacture of wafers or tablets , comprises the following 
peutic or non - therapeutic applications , such as described composition : 
above . The label on the container may indicate that the 
composition is used for a specific therapy or non - therapeutic 25 temozolomide 
application , and may also indicate directions for either in stearic acid 
vivo or in vitro use , such as those described above . The kit lipase 
cholesterol of the invention will typically comprise the container 12 mg glycerol behenate 70 mg 
described above and one or more other containers compris poloxamer F - 68 
ing materials desirable from a commercial and user stand - 30 polyanhydroglucuronic acid 
point , including buffers , diluents , filters , needles , syringes , 
and package inserts with instructions for use . The wafer compositions of this example can be processed 
EXAMPLES according to methods known to a person who is already skilled in the art as exemplified in Method 1 . Using the tablet 
compression method , the powders are first passed through a The following examples are included to demonstrate 100 mesh screen and then dry blended for 5 minutes prior to preferred embodiments of the invention . It should be appre 
ciated by those of skill in the art that the techniques compression . Using a Carver press or tablet press , the components for the drug containing layer are first added to disclosed in the examples which follow represent techniques 
discovered by the inventor to function well in the practice of 40 the tablet die followed by the hydrophobic powder as 
the invention , and thus can be considered to constitute described in Method 1 . The resulting compositions were then cured at 65° C . for 3 hours . Implant compositions were preferred modes for its practice . However , those of skill in prepared according to the Methods as described below . the art should , in light of the present disclosure , appreciate The components of the drug containing layers in the that many changes can be made in the specific embodiments 
which are disclosed and still obtain a like or similar result 45 scompositions of Methods 2 and 3 can also be processed by injection molding and then milled into finer particles prior to without departing from the spirit and scope of the invention . compression into wafers that are 1 . 5 cm in diameter and 3 
Example 1 mm thick . The implants are then cured for 2 hours at 65° C . A trilayered implant composition according to the present 









In the following examples , Layer 1 is always the side 
positioned proximal , or directly against the brain tissue in 
the resection cavity . 
An embodiment of the present invention provides a wafer 55 
or composition comprising : 
















Layer 3 . 












The compressed wafers were cured at 60° C . for 8 hours . 
Another preferred embodiment of the present invention 
has a composition of : 
Layer 3 10 % 
5 % Stearic acid 
Glyceryl behenate 5 % 65 Layer 1 Chitosan 
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- continued heating the powder blend to approximately 120° C . for five 
minutes . The resulting mass was then cooled , milled and 
Layer 2 70 % passed through a 60 mesh screen , before incorporation into cisplatin 20 % the three layer wafer using the method described in Method glyceryl behenate 40 % 
stearic acid 10 % 5 1 . 
polyethylene oxide 0 . 5M 20 % Method 3 . A further embodiment of the present invention polyanhydroglucuronic acid 10 % involves the composition of Method 1 , when the glyceryl Layer 3 Glycerol behenate 14 % behenate and paclitaxel in Layer 2 are first blended together 
and then melt granulated by heating the powder to 120° C . 
The polyanhydroglucuronic acid ( Surgicel® ) was cryo - 10 for five minutes . When this mass was cooled and passed 
genically processed and then ground into fine powder . The through a 60 mesh screen , the polyethylene oxide compo 
composition is wet granulated with purified water , dried , nent of Layer 2 was then added to form the final powder 
passed through a 20 mesh screen and then processed into blend for Layer 2 , which was then incorporated into the 
500 mg wafers according to the processing methods outlined trilayered wafer formulation and then processed according 
in Method 1 . Circular wafers were then cured at 65° C . for 15 to the method described in Method 1 . 
2 hours . Method 4 . A further embodiment of the present invention 
Bevacizumab ( 20 % Layer 2 ) and Methotraxate ( 20 % provides a trilayered wafer implant composition of Method 
Layer 2 ) implants were prepared according to Method 6 and 3 where the sides and top lipophilic layer of the wafer were 
heat cured at 70° C . for 2 hours . coated , in lieu of glyceryl behenate , with an organic solution 
A further embodiment of the present invention for the 20 for the 20 of a Resomer® RG 756 S biodegradable polymer ( 5 % W / W 
manufacture of a trilayered film composition comprising the in acetone ) , ( Resomer® RG 756S ) leaving the bioadhesive 
following ingredients : layer ( Layer 1 ) , uncoated , and cured at 72° C . for 10 minutes . 
Method 5 . A further embodiment of the present invention 
25 provided a coated three layered wafer composition to con Layer 1 Polyethylene oxide 4M 20 % 
Layer 2 tain carboplatin 3 mg , and docetaxel 5 mg , as the active 70 % 
Irinotecan 8 % ingredients in a 350 mg trilayered wafer , prepared by the 
Lipase 0 . 5 % method outlined in Method 3 . 
Stearic acid 14 % Method 6 . A further embodiment of the present invention Glyceryl behenate 49 % provides for the manufacture of trilayered wafers each Pitavastatin 3 . 5 % 
Poloxamer F68 comprising the following composition : 10 % 
Polyethylene oxide 0 . 9M 15 % 
Layer 3 Glyceryl behenate 10 % 
Layer 1 polyethylene oxide 7M 
Layer 2 dexamethasone sodium phosphate 
A film of polyethylene oxide is prepared by hot melt 35 paclitaxel 
extrusion at process temperatures in the extruder ranging glyceryl behenate 
from 75° C . to 95° C . To this film , a molten composition is stearic acid polyethylene oxide 7M evenly spread and then cooled to room temperature . The Layer 3 glyceryl behenate 
glyceryl behenate in Layer 3 is melted and added onto the 
drug containing layer . The film is cooled and then cut into 40 40 All inert components were passed through a 70 mesh suitable sized wafers that are then heat cured at 68° C . for 
4 hours . screen . The trilayered wafer was prepared by first adding the 
Method 1 . An embodiment of the present invention pro polyethylene oxide 7M ( Layer 1 ) to a tablet die , followed by the powder blend containing the two active ingredients , vides a trilayer wafer or composition comprising : along with the glyceryl behenate and the stearic acid in the 
45 Layer 2 composition that had previously been melt granu 
Layer 1 Polyethylene oxide 7M 50 mg lated by heating the powders of Layer 2 to 120° C . for five 
Layer 2 200 mg minutes . When this mass was cooled and passed through a 
paclitaxel 8 mg 60 mesh screen , the polyethylene oxide component of Layer 
glyceryl behenate 185 mg 2 was then added to form the final powder blend for Layer polyethylene oxide 7M 7 mg 
Layer 3 glyceryl behenate 100 mg 2 , which was then incorporated into the trilayered wafer 
formulation . The melt granulated glyceryl behenate ( Layer 
3 ) was then added to the die , prior to compression into a All inert components were passed through a 70 mesh trilayered wafer . The sides of the circular trilayered wafer screen . A trilayered wafer was prepared by first adding the and the top lipophilic wax layer ( Layer 3 ) were then coated polyethylene oxide 7M ( Layer 1 ) to the tablet die , followed 55 with molten glyceryl behenate leaving the bioadhesive layer by the powder blend containing paclitaxel , glyceryl behen ( Layer 1 ) uncoated . ate and the polyethylene oxide ( Layer 2 ) . The glyceryl Method 7 . A further embodiment of the present invention 
behenate ( Layer 3 ) was first melted at 120° C . , cooled and of composition in Example 6 provides a trilayered wafer that 
passed through a 60 mesh screen and then added to the die was cured at approximately 72° C . for ten minutes . prior to compression into a trilayered wafer . The sides of the 60 Method 8 . A further embodiment of the present invention circular trilayered wafer and the top lipophilic wax layer provides for the manufacture of trilayered wafers or tablets 
( Layer 3 ) were then coated with molten glyceryl behenate at each comprising the following composition : 98° C . , leaving the bioadhesive layer ( Layer 1 ) uncoated and 
was then cured at approximately 72° C . for ten minutes . 
Method 2 . A composition of Method 1 was prepared 65 Layer 1 . polyethylene oxide 7M 50 mg 
where the three powders of the drug containing layer ( Layer Layer 2 . temozolomide 











US 9 , 956 , 172 B2 
30 
The sides of the circular trilayered wafer and the top 
lipophilic wax layer ( Layer 3 ) were then coated with molten 
glyceryl behenate , leaving the bioadhesive layer ( Layer 1 ) 
uncoated . The coated wafers were then heat treated at 60° C . 10 mg 
105 mg 5 for 5 minutes . 
8 mg Method 11 . A further embodiment of the present invention 
25 mg 
40 mg provides a bilayered wafer implant composition comprised 



















All inert components were passed through a 70 mesh Layer 1 carboplatin 
screen , except for the polyanhydroglucuronic acid which docetaxel 
was passed through a 40 mesh screen . A trilayered wafer was glyceryl behenate polyethylene oxide 7M prepared by first adding the polyethylene oxide 7M ( Layer lipase 
1 ) to the tablet die , followed by the powders of the drug 15 Layer 2 palmitic acid 
containing layer ( Layer 2 ) , which had been previously glyceryl behenate 
blended together and wet granulated with water and then 
melt granulated by heating the powder blend to approxi The inert components of Layer 1 were dry blended and 
mately 120° C . for five minutes . The resulting mass was then then passed through an 70 mesh screen . Using water as the 
cooled and milled before passing through a 40 mesh screen . 20 granulating agent , the powder blend was then wet granu 
The powder blend of stearic acid and glyceryl behenate lated . The granules were dried for four hours at 60° C . , were 
( Layer 3 ) was melt granulated and cooled before passing passed through a 60 mesh screen and then melt granulated 
through a 60 mesh screen and then added to the die prior to by heating the power blend at 110° C . for four minutes . The 
compression into a trilayered wafer . The sides and the top 25 resulting mass was cooled and then passed through a 30 
lipophilic wax layer ( Layer 3 ) of the circular trilayered mesh screen . The bilayered wafers were prepared by adding 
wafer were then coated with molten glyceryl behenate , the components from Layer 1 to the tablet die , followed by 
leaving the bioadhesive layer ( Layer 1 ) uncoated . The the powder from Layer 2 to the tablet die , in compositions 
coated wafer was then cured at approximately 74° C . for 8 as described above . The bilayered wafers were then com 
minutes . 30 pressed and cured at 62° C . for eight minutes . 
Method 9 . A further embodiment of the present invention Method 12 . A further example of the present invention 
provides for the uncoated trilayered wafer of Method 6 , to provides for the uncoated bilayered wafers of Method 11 to 
contain irinotecan 12 mg in place of the temozolomide . The have the sides and the top lipophilic wax layer ( Layer 2 ) of 
sides and the top lipophilic wax layer ( Layer 3 ) of the the bilayered wafer coated with molten glyceryl behenated , 
trilayered wafer were then coated with a 5 % w / w acetone 35 leaving the bioadhesive layer ( Layer 1 ) uncoated . The 
solution of PLGA ( Resomer® RG 756S ) , and cured at 60° coated wafers were then heat treated at 70° C . for 5 minutes . 





Layer 1 paclitaxel 11 mg 
Layer 1 chitosan 30 mg dexamethasone sodium phosphate polyethylene glycol 100 , 000 glyceryl behenate 207 mg polyethylene oxide 1M 15 mg polyethylene oxide 7M 13 mg Layer 2 carboplatin 3 mg lipase 2 mg 
atorvastin 1 . 5 mg Layer 2 palmitic acid 48 mg cisplatin mg glyceryl behenate 112 mg 
stearic acid 212 mg 
lipase 1 . 5 mg 
glyceryl tristearate 20 mg The inert components of Layer 1 were dry blended and polyethylene oxide 0 . 9M 8 mg 
Layer 3 stearic acid 20 mg then passed through an 70 mesh screen . Using water as the 
glyceryl behenate 80 mg granulating agent , the powder blend was then wet granu 
lated . The dried granules were passed through a 60 mesh 
All inert components were prescreened to remove lumps screen and then melt granulated by heating the power 
and aggregates . A trilayered wafer was prepared by first 55 blender 110° C . for four minutes . The resulting mass was 
blending the components of Layer 1 , including chitosan , cooled and then passed through a 30 mesh screen . The 
polyethylene glycol , and polyethylene oxide , into a uniform bilayered wafers were prepared by adding the components 
composition . This material was then added to the tablet die . from Layer 1 to the tablet die , followed by the melt 
The three active ingredients in Layer 2 , were blended granulated powder from Layer 2 to the tablet die , in com 
together and then incorporated with the remaining powders 60 positions as described above . The bilayered wafers were 
in Layer 2 and melt granulated by heating the powder blend then compressed and heated at 70° C . for eight minutes . 
to approximately 120° C . for ten minutes . Method 14 . A further example of the present invention 
The resulting mass was cooled and milled by passing provides for the uncoated trilayered wafers of Method 9 to 
through a 60 mesh screen . The granulation from Layer 2 was have the sides and the top lipophilic wax layer ( Layer 2 ) of 
then added to the tablet die , followed by the stearic acid and 65 the bilayered wafer coated with molten glyceryl behenated , 
glyceryl behenate melt granulated powder blend that formed leaving the bioadhesive layer ( Layer 1 ) uncoated . The 
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Method 15 . A further embodiment of the present inven All inert components were passed through a 70 mesh 
tion provides a trilayered implant composition comprising screen . The trilayered wafer was prepared by first adding the 
the following ingredients : polyethylene oxide 7M ( Layer 1 ) to a tablet die . The powder 
blend containing the dexamethasone sodium phosphate and 
methotrexate was added to the glyceryl behenate and the Layer 1 polyethylene oxide 1M 
Polyethylene oxide 7M stearic acid in the Layer 2 composition . The two lipids had 
Layer 2 bevacizumab 2 mg previously been melt granulated by heating the powders of 
cetuximab 1 . 5 mg Layer 2 to 110° C . for five minutes . When this mass had 
everolimus 4 . 5 mg been cooled and passed through a 60 mesh screen , the glyceryl behenate 185 mg 
polyethylene oxide ( 100 , 000 MW ) polyethylene oxide component of Layer 2 was then added to 
Layer 3 glyceryl behenate 85 mg form the final powder blend for Layer 2 , which was then 
stearic acid 10 mg incorporated into the trilayered wafer formulation . The melt 
Cholesterol 5 mg granulated glyceryl behenate ( Layer 3 ) was then added to 
the die , prior to compression into a trilayered wafer . The 
All inert components are first prescreened to remove 15 sides of the circular trilayered wafer and the top lipophilic 
lumps and aggregates . A trilayered wafer is prepared by first wax layer ( Layer 3 ) were then coated with molten glyceryl 
blending the two components of Layer 1 into a uniform behenate at approximately 90° C . , leaving the bioadhesive 
composition . 50 mg of this material is then added to the material is then added to the layer ( Layer 1 ) uncoated and then cured at approximately 
tablet die . 72° C . for ten minutes . 
The three active ingredients in Layer 2 are blended and 20 Method 18 : A further embodiment of the present compo 
then further mixed with the glyceryl behenate and the sition provides for the manufacture of trilayered wafers 
polyethylene oxide excipients . This powder is then melted comprising carmustine as the active ingredient using the 
granulated by heating the powder blend to approximately composition and method of preparation as described below . 
100° C . for six minutes . 
The resulting mass is then cooled and milled by passing 25 
through a 60 mesh screen . 200 mg of this granulation is then Layer 1 polyethylene oxide 7M 50 mg Layer 2 carmustine 20 mg added to the tablet die , followed by 100 mg of the granulated glyceryl behenate 174 mg 
blended ingredients comprising Layer 3 . The sides of the polyethylene oxide 7M 
circular trilayered compressed wafer and the top lipophilic Layer 3 Glyceryl behenate 
wax layer ( Layer 3 ) are then coated with molten glyceryl 30 
behenate , leaving the bioadhesive layer ( Layer 1 ) uncoated . All inert components are passed through an 80 mesh 
The coated wafers are then heat treated at 72° C . for four screen . The trilayered wafer is prepared by first adding the minutes . polyethylene oxide 7M ( Layer 1 ) to a tablet die . The powder Method 16 . A further embodiment of the present inven blend containing the carmustine is added to the glyceryl tion for the manufacture of a trilayered film comprises the 35 behenate in the Layer 2 composition . The lipid is melt following ingredients : granulated by heating the powders of Layer 2 to 90° C . for 
two minutes . When this mass is cooled and passed through 
Layer 1 polyethylene oxide 4M 20 % a 60 mesh screen , the polyethylene oxide component of 
Layer 2 epirubicin HCl 8 % Layer 2 is then added to form the final powder blend for 
lipase 0 . 5 % Layer 2 and is added to the die . Then the melt granulated 
stearic acid 14 % glyceryl behenate ( Layer 3 ) is added to the die , prior to glyceryl behenate 49 % 
pitavastatin 3 . 5 % compression into a trilayered wafer . The sides of the circular 
poloxamer F68 10 % trilayered wafer and the top lipophilic wax layer ( Layer 3 ) 
polyethylene oxide 0 . 9M 15 % were then coated with molten glyceryl behenate leaving the Layer 3 glyceryl behenate 10 % bioadhesive layer ( Layer 1 ) uncoated and then cured at 
approximately 72° C . for ten minutes . 
A film of polyethylene oxide is prepared by hot melt Method 19 : A further embodiment of the present compo 
extrusion at processing temperatures in the extruder ranging s ition provides for the manufacture of trilayered wafers 
from 75° C . to 140° C . To this film , a molten compositions comprising doxorubicin as the active ingredient using the 
of Layer 2 is evenly spread and then cooled to room composition and method of preparation as described below . 
temperature . The glyceryl behenate in Layer 3 is melted and 
added onto the drug containing layer . The film is cooled and 
then cut into suitable sized wafers that are then heat cured at Layer 1 polyethylene oxide 7M 
68° C . for 4 hours . Layer 2 doxorubicin glyceryl behenate 
Method 17 : A further embodiment of the present inven polyethylene oxide 7M 
tion provides for the manufacture of trilayered wafers com Layer 3 Glyceryl behenate 
prised of the following composition : 
All inert components are passed through an 80 mesh 
60 screen . The trilayered wafer is prepared by first adding the Layer 1 polyethylene oxide 7M 
Layer 2 methotrexate polyethylene oxide 7M ( Layer 1 ) to a tablet die . The powder 
dexamethasone sodium phosphate blend containing the doxorubicin is added to the glyceryl 
glyceryl behenate behenate in the Layer 2 composition . The lipid and drug are 
stearic acid melt granulated by heating the powders of Layer 2 to 90° C . polyethylene oxide 7M 8 mg 
Layer 3 glyceryl behenate 100 mg 65 for one minute . When this mass is cooled and passed through 
a 60 mesh screen , the polyethylene oxide component of 

















Layer 2 and is added to the die . Then the melt granulated lamine as the active ingredient using the composition and 
glyceryl behenate ( Layer 3 ) is added to the die , prior to method of preparation as described in Method 19 . 
compression into a trilayered wafer . The sides of the circular 
trilayered wafer and the top lipophilic wax layer ( Layer 3 ) 
are then coated with molten glyceryl behenate leaving the 5 Layer 1 polyethylene oxide 7M Layer 2 D - penicillamine 40 mg 
bioadhesive layer ( Layer 1 ) uncoated and then cured at glyceryl behenate 156 mg 
approximately 70° C . for fifteen minutes . polyethylene oxide 1M 
Method 20 : A further embodiment of the present compo Layer 3 Glyceryl behenate 100 mg 
sition provides for the manufacture of trilayered wafers 
comprising topotecan as the active ingredient using the All inert components are passed through an 80 mesh 
composition and method of preparation as described in screen . The trilayered wafer is prepared by first adding the 
Method 19 . polyethylene oxide 7M ( Layer 1 ) to a tablet die . The powder 
blend containing the D - penicillamine is added to the glyc 
eryl behenate in the Layer 2 composition . The lipid and drug Layer 1 polyethylene oxide 7M 25 mg are melt granulated by heating the powders of Layer 2 to 90° Layer 2 topotecan 10 mg 
glyceryl behenate 182 mg C . for one minute . When this mass is cooled and passed 
polyethylene oxide 7M 8 mg through a 60 mesh screen , the polyethylene oxide compo 
Layer 3 Glyceryl behenate 75 mg nent of Layer 2 is then added to form the final powder blend 
20 for Layer 2 and is added to the die . Then , melt granulated 
All inert components are passed through an 80 mesh glyceryl behenate ( Layer 3 ) is added to the die , prior to 
screen . The trilayered wafer is prepared by first adding the compression into a trilayered wafer . The sides of the circular 
polyethylene oxide 7M ( Layer 1 ) to a tablet die . The powder trilayered wafer and the top lipophilic wax layer ( Layer 3 ) 
blend containing the topotecan is added to the glyceryl are then coated with molten glyceryl behenate leaving the 
behenate in the Layer 2 composition . The lipid and drug are 25 bioadhesive layer ( Layer 1 ) uncoated . 
melt granulated by heating the powders of Layer 2 to 90° C . Method 23 : A further embodiment of the present compo 
for one minute . When this mass is cooled and passed through sition provides for the manufacture of trilayered wafers 
a 60 mesh screen , the polyethylene oxide component of comprising a copper chelating agent such as D - penicil 
Layer 2 is then added to form the final powder blend for lamine and paclitaxel as the active ingredient using the 
Layer 2 and is added to the die . Then , melt granulated 30 composition and method of preparation as described below . 
glyceryl behenate ( Layer 3 ) is added to the die , prior to 
compression into a trilayered wafer . The sides of the circular Layer 1 polyethylene oxide 7M trilayered wafer and the top lipophilic wax layer ( Layer 3 ) Layer 2 D - penicillamine 30 mg 
are then coated with molten glyceryl behenate leaving the 25 Paclitaxel 10 mg 
bioadhesive layer ( Layer 1 ) uncoated and then cured at glyceryl behenate 156 mg 
approximately 73° C . for ten minutes . polyethylene oxide 1M 4 mg Layer 3 Glyceryl behenate 100 mg Method 21 : A further embodiment of the present compo 
sition provides for the manufacture of trilayered wafers 
comprising D - actinomycin as the active ingredient using the an All inert components are passed through an 80 mesh 
composition and method of preparation as described in * screen . The trilayered wafer is prepared by first adding the 
Method 19 . polyethylene oxide 7M ( Layer 1 ) to a tablet die . The powder blend containing the D - penicillamine and paclitaxel is added 
to the glyceryl behenate in the Layer 2 composition . The 
Layer 1 polyethylene oxide 7M 35 mg lipid and drugs are melt granulated by heating the powders 
Layer 2 D - actinomycin 45 of Layer 2 to 90° C . for one minute . When this mass is glyceryl behenate cooled and passed through a 60 mesh screen , the polyeth polyethylene oxide 7M 
Layer 3 Glyceryl behenate 100 mg ylene oxide component of Layer 2 is then added to form the 
final powder blend for Layer 2 and is added to the die . Then , 
melt granulated glyceryl behenate ( Layer 3 ) is added to the All inert components are passed through an 80 mesh 50 a die , prior to compression into a trilayered wafer . The sides screen . The trilayered wafer is prepared by first adding the of the circular trilayered wafer and the top lipophilic wax polyethylene oxide 7M ( Layer 1 ) to a tablet die . The powder layer ( Layer 3 ) are then coated with molten glyceryl behen blend containing the D - actinomycin is added to the glyceryl ate leaving the bioadhesive layer ( Layer 1 ) uncoated . behenate in the Layer 2 composition . The lipid and drug are Method 24 : A further embodiment of the present compo melt granulated by heating the powders of Layer 2 to 90° C . 55 siti sition provides for the manufacture of trilayered wafers for one minute . When this mass is cooled and passed through comprising a synthetic alkyl lysophospholipid such as edel a 60 mesh screen , the polyethylene oxide component of fosine and paclitaxel as the active ingredients using the Layer 2 is then added to form the final powder blend for composition and method of preparation as described below . Layer 2 and is added to the die . Then , melt granulated 
glyceryl behenate ( Layer 3 ) is added to the die , prior to 60 
compression into a trilayered wafer . The sides of the circular Layer 1 polyethylene oxide 7M 
trilayered wafer and the top lipophilic wax layer ( Layer 3 ) Layer 2 Edelfosine 1 mg 
are then coated with molten glyceryl behenate leaving the Paclitaxel 10 mg 
bioadhesive layer ( Layer 1 ) uncoated . glyceryl behenate 182 mg polyethylene oxide 1M 7 mg 
Method 22 : A further embodiment of the present compo - 65 Layer 3 Glyceryl behenate 
sition provides for the manufacture of trilayered wafers 
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All inert components are passed through an 80 mesh granules were then passed through a 60 mesh stainless 
screen . The trilayered wafer is prepared by first adding the screen to obtain a dispersion of acetaminophen in Compri 
polyethylene oxide 7M ( Layer 1 ) to a tablet die . The powder tol® . 
blend containing the edelfosine and paclitaxel is added to the Preparation of Acetaminophen Wafers for Implant : 
glyceryl behenate in the Layer 2 composition . The lipid and 5 Three types of implant wafers , single layer , bilayer and 
drugs are melt granulated by heating the powders of Layer tri - layer , were prepared in this study . As shown in FIG . 1 , 
2 to 90° C . for one minute . When this mass is cooled and single layer wafer contained 200 mg drug layer only . Bilayer 
passed through a 60 mesh screen , the polyethylene oxide wafer was consisting of a 200 mg drug layer and 100 mg 
component of Layer 2 is then added to form the final powder Compritol layer . In tri - layer wafer , 200 mg drug layer is 
blend for Layer 2 and is added to the die . Then , melt sandwiched between 100 mg Compritol layer and 50 mg 
granulated glyceryl behenate ( Layer 3 ) is added to the die , PolyOx layer . 
prior to compression into a trilayered wafer . The sides of the An 11 mm in diameter , round and flat - faced tableting 
circular trilayered wafer and the top lipophilic wax layer tooling was used to prepare the wafers . Powder blends for 
( Layer 3 ) are then coated with molten glyceryl behenate 15 each individual layer were filled into die on a layer by layer 
leaving the bioadhesive layer ( Layer 1 ) uncoated . fashion . The powder was compressed with a Carver press 
Method 25 : A further embodiment of the present compo ( Model MTCM - 1 , Globepharma , New Brunswick , N . J . , 
sition provides for the manufacture of trilayered wafers US ) . The compression force was kept at 3000 psi . 
comprising a bioactive sulfated saponin such as Sponin - 1 Coating and Curing of Wafers for Implant : 
( SAP - 1 ) as the active ingredient using the composition and 20 Wafers were coated with a hydrophobic wax or polymer . 
method of preparation as described below . Curing of wafers was performed using the column oven in 
a gas chromatography system ( Agilent , Model GC 7820A , 
Santa Clara , Calif . US ) . The wafers were cured at 73° C . for Layer 1 polyethylene oxide 7M 50 mg 
Layer 2 30 mg SAP - 1 a total of 10 minutes . 
glyceryl behenate 166 mg 25 In Vitro Drug Release Testing : 
polyethylene oxide 1M Each implant was placed inside a 20 mL glass scintillation Layer 3 Glyceryl behenate 100 mg vial . Twenty milliliter 50 mM phosphate buffer pH 7 . 4 was 
added into each vial as the dissolution medium . The vials 
All inert components are passed through an 80 mesh were stored inside an incubator chamber set at 37° C . Three 
screen . The trilayered wafer is prepared by first adding the 30 milliliter dissolution medium was sampled at pre - deter 
polyethylene oxide 7M ( Layer 1 ) to a tablet die . The powder mined time points . The buffer solution was used to replace 
blend containing SAP - 1 is added to the glyceryl behenate in the dissolution medium withdrawn at the time of sampling . 
the Layer 2 composition . The lipid and drug are physically HPLC for the Quantitation of Acetaminophen in Disso 
blended with the polyethylene oxide component of Layer 2 lution Samples : 
to form the final powder blend for Layer 2 and is added to 35 Dissolution samples were analyzed using a reversed phase 
the die . Then , melt granulated glyceryl behenate ( Layer 3 ) is HPLC method . Poroshell® 120 , EC - C18 , 2 . 7 um , 4 . 6x50 
added to the die , prior to compression into a trilayered wafer . mm ( Agilent , Santa Clara , Calif . , USA ) was used as the 
The sides of the circular trilayered wafer and the top HPLC column . A mixture of water and acetonitrile mixture 
lipophilic wax layer ( Layer 3 ) are then coated with molten ( 95 : 5 ratio ) containing 0 . 05 % trifluoroacetic acid was used 
glyceryl behenate leaving the bioadhesive layer ( Layer 1 ) 40 as the mobile phase . The flow rate was set at 1 . 0 mL / min and 
uncoated . the injection volume was 10 uL . A UV detector ( Waters 
2998 PDA detector , Milford , Mass . ) was used to quantitate 
Example 2 at 275 nm . The retention time of acetaminophen was 2 . 1 
minutes . 
Generation of Multi - Layered Implants and 45 Differential Scanning Thermal Analysis : 
Physiochemical Properties Differential scanning calorimetry testing was performed 
using a TA Thermal Analyzer ( Model DSC Q20 , TA Instru 
Materials and Methods ments , New Castle , Del . , US ) . The temperature was cali 
Materials : brated with an indium standard . Sample size was about 5 mg 
Acetaminophen , USP , was purchased from Spectrum 50 and a temperature ramp of 10° C . per minute was used . 
Chemical ( Gardena , Calif . , USA ) . Compritol 888 ATO was Universal Analysis 2000 data analysis software was used for 
generously provided by Gattefosse ( Paramus , N . J . , USA ) . data analysis . Inflection point method was used for the 
Poly ( ethylene oxide ) was generously donated in three dif - analysis of the glass transition temperature . The melting 
ferent grades ( PolyOx N10 , N12K , and 303 ) by Dow temperature is defined as the intersection of the extension of 
Chemical ( Midland , Mich . , USA ) . All other chemicals uti - 55 the baseline with the tangent at the inflection point of the 
lized in this study were of AC S grade . curve . 
Dispersion of Acetaminophen in Compritol® : Powder X - Ray Diffraction : 
Acetaminophen and Compritol® were passed through a Powder X - ray diffraction ( PXRD ) was performed using a 
70 mesh stainless steel screen prior to use . Homogenous Rigaku Miniflex instrument ( Rigaku , Woodlands , Tex . , US ) . 
blends of Compritol® and acetaminophen were prepared via 60 A Cu Ka ( a = 1 . 54 Å ) radiation with Ni filter , was used with 
geometric dilution using a mortar and pestle . The blend was a voltage of 40 kV , and a current of 100 mA . Samples of 
placed for 5 minutes inside an oven set at 80° C . to melt powder were placed into channeled stage and continuous 
Compritol® . Under constant mixing of a stirring rod , dis - scans were made from 10° to 40° 20 with a step size of 
persion of acetaminophen in the molten Compritol® was 0 . 05º . 
poured onto an aluminum tray to allow Compritol® to 65 Scanning Electron Microscopy : 
solidify at ambient conditions . The solidified wax was Scanning electron microscopy ( SEM ) was performed 
ground up into small granules using a mortar and pestle . The according to established protocols . 
37 
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Results from these experiments are shown in FIGS . 1 - 6 . U . S . Pat . No . 3 , 364 , 200 , " Oxidized Cellulose Product and 
As shown in the figures drug release from the wafers was Method for Preparing the Same ” , W . Ashton , C . Moser , 
observed over a period of days . It is anticipated that this Jan . 16 , 1968 . 
pharmacokinetic profile may be advantageously used to M . Aburahma , S . Badr - Eldin , “ Compritol 888 ATO : A 
deliver a therapeutic compound to the brain . 5 Multifactional Lipid Excipient in Drug Delivery Systems 
As shown in FIG . 1 , release of acetaminophen ( APAP ) and Nanopharmaceuticals ” , Expert Opinion on Drug 
from single laver ( drug laver only ) wafer was observed . Delivery , 11 ( 12 ) , p 1865 - 1883 , 2014 . 
Composition : 5 % APAP , certain percent of PEO 303 ( 7 , 000 , F . Kreye , F . Siepmann , J . Siepmann , “ Drug Release Mecha 
000 molar mass ) , and glycerol behenate q . s . to 100 % , a total nisms of Compressed Lipid Implants ” , International 
of 200 mg . Objective : to investigate the percent of PEO on 10 Journal of Pharmaceutics , 404 ( 1 - 2 ) , p 27 - 35 , 2011 . K . Forier , K . Raemdonch , S . De Smedt , J . Demeester , T . drug release from drug layer only wafer . Conclusion : levels coenye , K . Braeckmans , “ Lipid and Polymer Nanopar of PEO 303 between 1 . 5 and 4 % were observed to be ticles for Drug Delivery to Bacterial Biofilms ” , Journal of particularly effective . Controlled Release , 190 , p 607 - 623 , 2014 . Additional results are shown in FIGS . 2 - 6 . A diagram of 15 K diagram of 15 K . Cho , X . Wang , S . Nie , Z . Chen , D . Shin , “ Therapeutic ? 
a multi - layered implant is shown in FIG . 7 . Effect of the Nanoparticle for Drug Delivery in Cancer " , Clinical Can 
Molecular Weight and Percent of PolyOx on Drug Release cer Research . 14 . p 1310 . 2008 . 
from Coated Bilayer Wafer Implants was evaluated ( N10 , S . Kalepu , M . Manthina . V . Padavala , “ Oral Lipid - Based 
N12K and 303 at 0 , 1 . 5 and 3 . 0 % , w / w Lot 15 - ) . Effect of Drug Delivery Systems — An Overview ” , Acta Pharma 
the Molecular Weight and Percent of PolyOx on Drug 20 ceutica Sinica B , 3 ( 6 ) , p 361 - 372 , 2013 . 
Release from Coated Bilayer Wafer Implants ( N10 , N12K S . Zara , M . Nabila , “ Optimizing Oral Drug Delivery Using 
and 303 at 0 , 4 . 0 and 5 . 0 % , w / w Lot 16 - ) was evaluated . Lipid Based Formulations ” , International Research Jour 
Effect of wax coating and bioadhesive layer on drug release nal of Pharmacy , 5 ( 7 ) , 2014 . 
from wafers ( 3 % 303 , 17 - 1 : single layer ; 17 - 3 : coated M . Schwab , G . Sax , S . Schulze , G . Winter , “ Studies on the 
bilayer : 17 - 5 : coated tri - layer ) was evaluated . Effect of 25 Lipase Induced Degradation of Lipid Based Drug Deliv 
curing was evaluated . Solubility of APAP in Compritol wax ery Systems ” , Journal of Controlled Release , 140 , p 
was evaluated . 27 - 33 , 2009 . 
DSC results are shown in FIG . 6 . Obiective : analyze the F . Kreye , F . Siepmann , J . Siepmann , “ Lipid Implants as 
physical state of APAP in glycerol behenate , Is APAP behenate . Is APAP Drug Delivery Systems ” , Expert Opinion Drug Delivery , 
completed dissolved at molecular level or dispersed as 30 30 5 ( 3 ) , p 291 - 307 , 2008 . 
crystalline particles ? Conclusion : APAP is dispersed as L . Zhu , V . Kumar , G . Banker , “ Examination of Aqueous Oxidized Cellulose Dispersions as a Potential Drug Car crystalline particles . Physical blend : 5 % APAP + 95 % glyc rier . I . Preparation and Characterization of Oxidized Cel erol behenate . Melt mix : 5 % APAP + 95 % glycerol behenate lulose - Phenylpropanolamine Complexes ” , AAPS Pharm processed using the melt granulation process . Compritol 35 I process . Compritol 35 SciTech , 5 ( 4 ) , p 138 - 144 , 2004 . 
888 : glycerol behenate raw material , used as the reference . US . Pat . No . 6 . 488 . 963 B1 . J . McGinity and E . Zhang . 
APAP : drug substance , used as the control . “ Hot - Melt Extrudable Pharmaceutical Formulation ” , 
All of the methods disclosed and claimed herein can be Dec . 3 . 2002 . 
made and executed without undue experimentation in light M . Masserini . “ Nanoparticles for Brain Drug Delivery ” . 
of the present disclosure . While the compositions and meth - 40 International Scholarly Research Notices Biochemistry , 
ods of this invention have been described in terms of 2013 , Article ID 238428 , 2013 . 
preferred embodiments , it will be apparent to those of skill P . Menei , C . Montero - Menei , M . C . Venier , J . P Benoit . 
in the art that variations may be applied to the methods and “ Drug Delivery into the Brain Using Poly ( lactide - co 
in the steps or in the sequence of steps of the method glycolide ) Microspheres ” , Expert Opinion Drug Delivery , 
described herein without departing from the concept , spirit 45 2 ( 2 ) , 363 - 376 , 2005 . 
and scope of the invention . More specifically , it will be C . Carbone , A . Campisi , T . Musumeci , G . Raciti , R . Bon 
apparent that certain agents which are both chemically and fanti , G . Puglisi , “ FA - Loaded Lipid Drug Delivery Sys 
physiologically related may be substituted for the agents tems : Preparation , Characterization and Biological Stud 
described herein while the same or similar results would be ies ” , European Journal Pharmaceutical Sciences , 14 ( 52 ) 
achieved . All such similar substitutes and modifications 50 p 12 - 20 , 2014 . 
apparent to those skilled in the art are deemed to be within I . Shapira , D . Budman , T . Bradley , R . Gralla , “ Evolving 
the spirit , scope and concept of the invention as defined by Lipid - Based Delivery Systems in the Management of 
the appended claims . Neoplastic Disease ” , Oncology Reviews , 113 , 2009 . 
R . Upadhyay , “ Drug Delivery Systems , CNS Protection , and 
REFERENCES 55 the Blood Brain Barrier ” , BioMed Research International , 
2014 , Article ID 869269 , 2014 . 
The following references , to the extent that they provide W . Pardridge , “ Drug Delivery to the Brain ” , Journal of 
exemplary procedural or other details supplementary to Cerebral Blood Flow & Metabolism , 17 , p 713 - 731 , 1997 . 
those set forth herein , are specifically incorporated herein by R . Gabathuler , “ Approaches to Transport Therapeutic Drugs 
reference . 60 Across the Blood - Brain Barrier to Treat Brain Diseases " , 
U . S . Pat . No . 8 , 821 , 913 B2 , “ Controlled Releases System Neurobiology of Disease , 37 , p 48 - 57 , 2010 . 
Containing Temozolomide " , Y Wang , D . Fei , Sep . 2 , 2014 G . Tiwari , R . Riwari , B . Sriwastawa , L . Bhati , S . Pandey , S . 
D . Zhang , A . Tian . X . Xue , M . Wang , B . Qui , A . Wu , “ The Bannerjee , “ Drug Delivery Systems : An Updated Review , 
Effect of Temozolommide / Poly ( lactide - co - glycolide ) International Journal of Pharmaceutical Investigation , 
( PLGA ) / Nano - Hydroxyapatite Microspheres on Glioma 65 2 ( 1 ) , p 2 - 11 , 2012 . 
U87 Cells Behavior ” , International Journal of Molecular P . Jiang , R . Mukthavavam , Y . Chao , I . Bharati , V . Fogal , S . 
Sciences , 13 ( 1 ) , p 1109 - 1125 , 2012 . Pastorino , X . Cong , N . Nomura , M . Gallagher , T . Abbas , 
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S . Vali , S . Pingle , M . Makale , S . Kesari , " Novel Anti Weitman et al . , Cancer Res . , 52 ( 12 ) : 3396 - 3401 , 1992b . 
glioblastoma Agents and Therapeutic Combinations Iden Weitman et al . , Cancer Res . , 52 ( 23 ) : 6708 - 6711 , 1992a . 
tified from a Collection of FDA Approved Drugs ” , Jour Winkles , Nat Rev Drug Discov 7 : 411 - 425 ( 2008 ) . 
nal of Translational Medicine , 12 , 2014 . Winthrop et al . , Clin . Cancer Res . , 9 : 3845s - 3853s , 2003 . 
U . S . Patent Publication No . 2004 / 0005647 5 Zhou , Mol Cancer Ther . 10 ( 7 ) : 1276 - 88 , 2011 . 
U . S . Patent Publication No . 2006 / 0034925 What is claimed is : 
U . S . Patent Publication No . 2006 / 0115537 1 . A biocompatible drug delivery implant for positioning 
U . S . Patent Publication No . 2006 / 0223114 adjacent to a biological tissue for delivering one or more 
U . S . Patent Publication No . 2006 / 0234299 drugs thereto , the implant comprising at least two layers , a 
U . S . Patent Publication No . 2007 / 0148095 10 drug - containing layer having a drug elution surface to be 
U . S . Patent Publication No . 2012 / 0141550 positioned proximal to the tissue , and , a further layer or 
U . S . Patent Publication No . 2013 / 0138032 layers comprising a lipophilic backing layer and / or a hydro 
U . S . Patent Publication No . 2014 / 0024610 phobic coating , said further layer or layers being positioned 
U . S . Pat . No . 5 , 739 , 169 distal to the drug elution surface , wherein : 
U . S . Pat . No . 5 , 801 , 005 a ) the drug - containing layer comprises one or more drugs , 
U . S . Pat . No . 5 , 824 , 311 a hydrophilic polymer or pore forming agent , and 
U . S . Pat . No . 5 , 830 , 880 glyceryl behenate ; 
U . S . Pat . No . 5 , 846 , 945 b ) the lipophilic backing layer comprises glyceryl behen 
U . S . Pat . No . 6 , 232 , 287 ate ; and 
U . S . Pat . No . 6 , 528 , 481 20 c ) the hydrophobic coating comprises glyceryl behenate 
U . S . Pat . No . 7 , 452 , 964 and coats surfaces of the implant that are not to be 
U . S . Pat . No . 7 , 671 , 010 positioned proximal to the tissue and ; and 
U . S . Pat . No . 7 , 781 , 565 further , when each of layers a ) , b ) and c ) are present , the 
U . S . Pat . No . 8 , 507 , 445 lipophilic backing layer is positioned between the drug 
U . S . Pat . No . 8 , 450 , 278 25 containing layer and the hydrophobic coating . 
PCT Publication No . 2008 / 121949 2 . The implant of claim 1 , wherein the implant further 
PCT Publication No . 2011 / 053435 comprises a drug - permeable , hydrophilic layer d ) positioned 
PCT Publication No . 2014 / 087413 between the drug elution surface of the drug - containing 
Anderson , N . G . , Practical Process Research & Develop layer and to be positioned proximal to the tissue . 
ment - A Guide For Organic Chemists , 2nd ed . , Academic 30 3 . The implant of claim 2 , wherein the layer d ) contains 
Press , New York , 2012 . a steroid and the drug . 
Austin - Ward and Villaseca , Rev . Med . Chil . , 126 ( 7 ) : 838 - 45 , 4 . The implant of claim 3 , wherein the steroid is dexam 
1998 . ethasone . 
Barclay et al . ( eds . ) , The Leucocyte Antigen Facts Book , 5 . The implant of claim 1 , wherein the hydrophilic poly 
1993 , Academic Press . 35 mer present in layer a ) and / or d ) is a polyether or a 
Bukowski et al . , Clin . Cancer Res . , 4 ( 10 ) : 2337 - 47 , 1998 . polysaccharide . 
Burkly et al . : TWEAKing tissue remodeling by a multifunc - 6 . The implant of claim 5 , wherein the hydrophilic poly 
tional cytokine : role of TWEAK / Fn14 pathway in health mer is a polyethylene oxide , polypropylene oxide , or a 
and disease . Cytokine 40 : 1 - 16 ( 2007 ) . polyethylene glycol . 
Campbell et al . , Cancer Res . , 51 ( 19 ) : 5329 - 5338 1991 . 40 7 . The implant of claim 5 , wherein the polysaccharide is 
Christodoulides et al . , Microbiology , 144 ( Pt 11 ) : 3027 - 37 , chitosan or polyanhydroglucuronic acid . 
1998 . 8 . The implant of claim 1 , wherein the drug is an 
Davidson et al . , J . Immunother . , 21 ( 5 ) : 389 - 98 , 1998 . anti - cancer compound or a chemotherapeutic . 
Hanibuchi et al . , Int . J . Cancer , 78 ( 4 ) : 480 - 485 , 1998 . 9 . The implant of claim 8 , wherein the chemotherapeutic 
Hellstrand et al . , Acta Oncol . , 37 ( 4 ) : 347 - 353 , 1998 . 45 is temozolomide , paclitaxel , cetuximab , irinotecan , everoli 
Hui and Hashimoto , Infect . Immun . , 66 ( 11 ) : 5329 - 36 , 1998 . mus , carboplatin , or docetaxel . 
Ju et al . , Gene Ther . , 7 ( 19 ) : 1672 - 1679 , 2000 . 10 . The implant of claim 1 , wherein the implant is 
March ' s Advanced Organic Chemistry : Reactions , Mecha - substantially circular or elliptical in shape or is further 
nisms , and Structure , 2007 . defined as a wafer . 
Mitchell et al . , Ann . NY Acad . Sci . , 690 : 153 - 166 , 1993 . 50 11 . The implant of claim 1 , wherein the drug - containing 
Mitchell et al . , J . Clin . Oncol . , 8 ( 5 ) : 856 - 869 , 1990 . layer comprises glyceryl behenate , stearic acid , polyanhy 
Morton et al . , Arch . Surg . , 127 : 392 - 399 , 1992 . droglucuronic acid , or polyethylene oxide . 
Nechushtan et al . , 1997 12 . The implant of claim 1 , wherein the hydrophobic 
Onda et al . , Cancer Res . , 64 : 1419 - 1424 , 2004 . coating further comprises stearic acid , palmitic acid , cho 
Pietras et al . , Oncogene , 17 ( 17 ) : 2235 - 49 , 1998 . 55 lesterol , or chitosan . 
Qin et al . , Proc . Natl . Acad . Sci . USA , 95 ( 24 ) : 14411 - 14416 , 13 . The implant of claim 1 , wherein the drug - containing 
1998 . layer further comprises stearic acid , lipase , cholesterol , 
Ravindranath and Morton , Intern . Rev . Immunol . , 7 : 303 glyceryl tristearate , poloxamer F - 68 , and / or polyanhydrog 
329 , 1991 . lucuronic acid . 
Remington ' s Pharmaceutical Sciences , 15th Ed . , 1035 - 1038 60 14 . The implant of claim 1 , wherein the implant com 
and 1570 - 1580 , 1990 . prises : 0 . 1 - 50 % of the drug , 5 - 95 % of glyceryl behenate , and 
Remington ' s Pharmaceutical Sciences , 15th Ed . , 3 : 624 - 652 , about 3 - 50 % of the hydrophilic polymer or pore forming 
1990 . agent . 
Rosenberg et al . , Ann . Surg . 210 ( 4 ) : 474 - 548 , 1989 . 15 . The implant of claim 1 , comprising layers a ) and b ) . 
Rosenberg et al . , N . Engl . J . Med . , 319 : 1676 , 1988 . 65 16 . The implant of claim 1 , comprising layers a ) and c ) . 
Thompson ( ed . ) , 1994 , The Cytokine Handbook , Academic 17 . The implant of claim 1 , comprising layers a ) , b ) and 
Press , San Diego . c ) . 
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the drug . 
18 . The implant of claim 2 , wherein the layer d ) does not 43 . The implant of claim 41 , wherein the organic solvent 
contain the drug . is ethanol , dichloromethane , acetone , tetrahydrofuran , or 
19 . The implant of claim 2 , wherein the layer d ) contains ethyl acetate . 
a steroid . 44 . The implant of claim 1 , wherein the lipophilic backing 
20 . The implant of claim 2 , wherein the layer d ) contains 5 layer and the hydrophobic coating are made of the same or 
essentially the same compounds or mixture of compounds . 
21 . The implant of claim 6 , wherein the hydrophilic 45 . The implant of claim 44 , wherein the lipophilic 
polymer is a polyethylene oxide . backing layer and the hydrophobic coating together form a 
22 . The implant of claim 5 , wherein the hydrophilic substantially homogenous hydrophobic layer . 10 46 . The implant of claim 1 , wherein the lipophilic backing polymer is a polysaccharide . 
23 . The implant of claim 5 , wherein the hydrophilic layer and the hydrophobic coating comprise different com pounds . polymer comprises a mixture of a polyether and a polysac 47 . The implant of claim 1 , wherein the hydrophobic 
charide . coating consists of or consists essentially of glyceryl behen 24 . The implant of claim 23 , wherein the hydrophilic 15 ate . 
polymer is a mixture comprising polyethylene oxide and 48 . The implant of claim 1 , where the drug - containing 
chitosan . layer comprises glyceryl behenate and stearic acid , in com 
25 . The implant of claim 5 , wherein the hydrophilic bination with polyanhydroglucuronic acid and / or polyeth 
polymer is polyethylene oxide or polyanhydroglucuronic ylene oxide . 
acid . 20 49 . The implant of claim 48 , wherein the drug - containing 
26 . The implant of claim 5 , wherein the hydrophilic layer comprises glyceryl behenate , stearic acid , and poly 
polymer is polyethylene oxide , chitosan , povidone ( PVP or ethylene oxide . 
polyvinylpyrrolidone ) , or polyanhydroglucuronic acid . 50 . The implant of claim 48 , wherein the drug - containing 
27 . The implant of claim 8 , wherein the anti - cancer layer further comprises lipase , cholesterol , glyceryl tristear 
compound is a chemotherapy or a chemotherapeutic agent . 25 ate , and / or poloxamer F - 68 . 
28 . The implant of claim 1 , wherein the drug is cisplatin , 51 . The implant of claim 50 , wherein layer c ) and / or layer 
topotecan , bevacizumab , doxorubicin , everolimus , pacli - b ) contain lipase . 
taxel , irinotecan , carboplatin , D - actinomycin , docetaxel , 52 . The implant of claim 1 , wherein the drug - containing 
pitavastatin , methotrexate , temozolomide , epirubicin , cetux layer comprises polyethylene oxide or polyanhydroglucor 
imab , a copper chelating agent , carmustine , a synthetic alkyl 30 u 30 onic acid . 53 . The implant of claim 52 , wherein the drug - containing lysophospholipid , a bioactive sulfated saponin , steroid , or a 
statin . layer comprises polyethylene oxide , glycerol behenate , and / or cholesterol . 29 . The implant of any one of claim 1 , wherein the drug 54 . The implant of claim 1 , wherein the hydrophilic is a steroid . 35 polymer is a polyethylene oxide , a polysaccharide , a protein , 
30 . The implant of any one of claim 1 , wherein layer a ) an oxidized cellulose polymer , polyanhydroglucuronic acid , comprises both a chemotherapeutic agent and a steroid . a poloxomer , chitosan , or providone ( PVP ) . 
31 . The implant of claim 2 , wherein layer a ) comprises a 55 . The implant of claim 1 , wherein the implant further 
chemotherapeutic agent , and wherein the implant further comprises lipase . 
comprises the layer d ) , wherein layer d ) comprises a steroid . 40 56 . The implant of claim 1 , wherein the implant is 
32 . The implant of claim 31 , wherein layer a ) further configured for insertion into a resection cavity . 
comprises a steroid . 57 . The implant of claim 1 , wherein the implant has been 
33 . The implant of any one of claim 29 , wherein the cured at temperatures of at least about 40° C . , 45° C . , 50° C . , 
steroid is dexamethasone or dexamethasone sodium phos - 55° C . , 60° C . , 65° C . , 70° C . , 75° C . , 80° C . , 85° C . , 90° 
phate . 45 C . , 95° C . , 100° C . , or up to 200° C . 
34 . The implant of claim 30 , wherein chemotherapeutic 58 . The implant of claim 1 , wherein the implant has been 
agent is temozolomide or paclitaxel ; and wherein the steroid sterilized by gamma radiation , ethylene oxide , or electron 
is dexamethasone . beam radiation . 
35 . The implant of any one of claim 1 , wherein the 59 . The implant of claim 1 , wherein the implant or wafer 
implant is further defined as a wafer . 50 has been processed by compression , hot - melt extrusion , 
36 . The implant of claim 35 , wherein the wafer or tablet injection molding , dry powder coating , dipping , coating , 
is configured for insertion into a resection cavity . spraying , hot - melt granulation , casting , an evaporation tech 
37 . The implant of claim 1 , wherein the implant or wafer n ology , or any combination thereof . 
further comprises an additional therapeutic agent . 60 . The implant of claim 1 , wherein the implant is further 
38 . The implant of claim 37 , wherein the additional 55 defined as a bilayered implant or wafer . 
therapeutic agent is an antibiotic , an antimicrobial agent , a 61 . The implant of claim 1 , wherein the implant is further 
statin , an anti - fungal agent , an anti - viral agent , a steroid , an defined as a trilayered implant or wafer . 
anesthetic , a local anesthetic , or a NSAID . 62 . The implant of claim 1 , wherein the implant allows for 
39 . The implant of claim 38 , wherein the additional release of the drug over a period of at least 3 , 4 , 5 , 6 , 7 , 8 , 
therapeutic agent is an antibiotic or an antimicrobial agent . 60 9 , 10 , 11 , 12 , 13 , 14 , 15 , 16 , 17 , 18 , 19 , 20 , 21 , 22 , 23 , 24 , 
40 . The implant of claim 1 , wherein the implant does not 25 , 26 , 27 , 28 , 29 , or 30 or more days , or at least 1 , 2 , 3 , 4 , 
contain an organic solvent . 5 , or 6 weeks , or any range derivable therein . 
41 . The implant of claim 1 , wherein the implant contains 63 . The implant of claim 1 , wherein the implant further 
an organic solvent . comprises a surfactant , a carbohydrate , a polyol , a protein , 
42 . The implant of claim 41 , wherein the implant contains 65 a peptide , and / or an excipient . 
no more than a trace amount or a residual amount of the 64 . A method of treating a disease or traumatic injury in 
organic solvent . a mammalian subject , comprising administering into a 
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resection cavity in the subject the implant of claim 1 , 
wherein the drug elution surface is positioned proximal to 
the resection cavity , and , the further layer or layers com 
prising the lipophilic backing layer and / or the hydrophobic 
coating are positioned distal and / or lateral to the drug elution 5 
surface . 
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